FLUoxetine (Monograph)

Brand names: PROzac, PROzac Weekly, Sarafem
Drug class: Selective Serotonin-reuptake Inhibitors
- Serotonin-reuptake Inhibitors
- SSRIs
VA class: CN609
Chemical name: N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine hydrochloride
Molecular formula: C₁₇H₁₈F₃NO•HCl
CAS number: 56296-78-7

Medically reviewed by Drugs.com on Feb 5, 2024. Written by ASHP.

Warning

Antidepressants increased risk of suicidal thinking and behavior (suicidality) compared with placebo in children, adolescents, and young adults (18–24 years of age) with major depressive disorder and other psychiatric disorders; balance this risk with clinical need.¹ ⁴⁷⁰ ⁴⁷¹ Fluoxetine is not approved for use in pediatric patients except for patients with major depressive disorder or obsessive-compulsive disorder.¹ (See Pediatric Use under Cautions.)
In pooled data analyses, risk of suicidality was not increased in adults >24 years of age and was reduced in adults ≥65 years of age with antidepressant therapy compared with placebo.¹ ⁴⁷⁰ ⁴⁷¹
Depression and certain other psychiatric disorders are themselves associated with an increased risk of suicide.¹ ⁴⁷⁰ ⁴⁷¹
Appropriately monitor and closely observe all patients who are started on fluoxetine therapy for clinical worsening, suicidality, or unusual changes in behavior; involve family members and/or caregivers in this process.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ (See Worsening of Depression and Suicidality Risk under Cautions.)

Introduction

Antidepressant; selective serotonin-reuptake inhibitor (SSRI).¹ ² ¹⁶ ²⁸ ⁵⁰ ⁵¹

Uses for FLUoxetine

Major Depressive Disorder

Acute and maintenance treatment of major depressive disorder.¹ ² ³ ⁴ ¹⁵ ¹⁶ ⁶⁰ ⁶¹ ⁶³ ⁶⁵ ⁶⁶ ⁶⁷ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁷² ⁷³ ⁷⁴ ⁸⁰ ¹²² ¹⁷¹ ¹⁷⁶ ²⁰⁹ ²¹⁰ ³⁴⁵ ⁴⁰⁶ ⁴⁰⁷ ⁴¹³

APA states that effectiveness of antidepressants is generally comparable between and within classes of medications, including SSRIs, SNRIs, TCAs, MAO inhibitors, and other antidepressants (e.g., bupropion, mirtazapine, trazodone).^a Choose antidepressant based mainly on patient preference; nature of prior response to medication; safety, tolerability, and anticipated adverse effects; concurrent psychiatric and medical conditions; and specific properties of the medication (e.g., half-life, actions on CYP isoenzymes, other drug interactions).^a For most patients, an SSRI, SNRI, mirtazapine, or bupropion is considered optimal.^a Consult APA’s Practice Guidelines for the Treatment of Patients with Major Depressive Disorder for additional information.^a

Obsessive-Compulsive Disorder (OCD)

Acute and maintenance treatment of OCD.¹ ⁴⁰⁸ ⁴⁰⁹ ⁴¹³

Premenstrual Dysphoric Disorder (PMDD)

Management of PMDD (previously late luteal phase dysphoric disorder).³⁶¹ ³⁶² ³⁶³ ³⁶⁴ ³⁶⁶

Eating Disorders

Acute and maintenance treatment of moderate to severe bulimia nervosa (at least 3 bulimic episodes per week for 6 months).¹ ⁴¹⁰

SSRIs usually are preferred drugs in management of bulimia because of more favorable adverse effect profile.³⁶⁵

Also has been used for management of anorexia nervosa^{† [off-label]}.⁷⁷ ⁷⁸ ²⁵⁵ ³⁵⁵

Not recommended as the sole or primary treatment of anorexia nervosa^{† [off-label]}.³⁵⁵

Panic Disorder

Acute treatment of panic disorder with or without agoraphobia.¹ ⁷⁵ ¹⁷⁷ ⁴¹⁸ ⁴¹⁹ ⁴³⁵ ⁴³⁷

Bipolar Disorder

Short-term treatment of acute depressive episodes (alone^{† [off-label]} or in combination with olanzapine) in patients with bipolar I disorder (bipolar depression).¹ ³ ²¹⁷ ⁴⁴⁸ ⁵⁰⁷ ⁵⁰⁸

May cause manic reactions when used as monotherapy in some patients;¹ ⁶ ⁷⁰ ⁸⁵ ⁸⁶ ⁸⁷ ⁸⁸ ²³⁰ should not be used without mood stabilizing agents (e.g., lithium, lamotrigine).³⁸⁴

Obesity

Has been used for the short-term treatment of exogenous obesity^{† [off-label]}.¹²³ ¹⁶² ¹⁹⁵ ²²⁸

Cataplexy

Has been used for the symptomatic management of cataplexy^{† [off-label]} in a limited number of patients with cataplexy and associated narcolepsy.¹²⁹

Alcohol Dependence

Has been used in the management of alcohol dependence^†.²¹⁷ ²¹⁹

Studies of SSRIs have generally shown modest effects on alcohol consumption.³⁸¹ ³⁸²

Myoclonus

Has been used for management of intention myoclonus^†, including postanoxic action myoclonus^† and progressive action myoclonus^† in a limited number of patients.¹²⁵

Premature Ejaculation

Like some other SSRIs, has been used for the treatment of premature ejaculation^†.³⁹³ ³⁹⁴

FLUoxetine Dosage and Administration

General

Allow at least 2 weeks to elapse between discontinuance of an MAO inhibitor and initiation of fluoxetine, and at least 5 weeks to elapse between discontinuance of fluoxetine and initiation of an MAO inhibitor or thioridazine.¹ (See Contraindications and also see Serotonin Syndrome or Neuroleptic Malignant Syndrome-like Reactions under Cautions.)
Monitor for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustments.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ (See Worsening of Depression and Suicidality Risk under Cautions.)
Sustained therapy may be required; periodically reassess need for continued therapy.¹
Avoid abrupt discontinuance.¹ Taper dosage gradually and monitor for withdrawal symptoms.¹ If intolerable symptoms occur following dosage reduction or discontinuance, consider reinstituting previously prescribed dosage, then resume more gradual dosage reductions.¹ (See Withdrawal of Therapy under Cautions.)
Consider cautiously tapering dosage during third trimester of pregnancy prior to delivery.¹ ⁴⁸⁰ ⁴⁸¹ ⁴⁸² ⁴⁹¹ (See Pregnancy under Cautions.)

Administration

Oral Administration

Administer conventional capsules, tablets, and solution orally once (in the morning)¹ ² ⁷⁰ or twice daily (preferably in the morning and at noon) without regard to meals.¹ ² ⁴ ⁷ ⁵⁸ ²¹⁷ If sedation occurs, the second dose may be administered at bedtime.²¹⁷

Administer delayed-release preparation once weekly without regard to meals.¹ ² ⁴ ⁷ ⁵⁸ ⁴⁰⁰ ⁴⁰¹

Administer fixed-combination fluoxetine/olanzapine capsules (Symbyax) once daily in the evening.⁴⁴⁸

Dosage

Available as fluoxetine hydrochloride; dosage is expressed in terms of fluoxetine.¹

Consider prolonged elimination half-life of fluoxetine and norfluoxetine (active metabolite) when titrating dosage or discontinuing therapy.¹ ² Several weeks may be required before full effect of dosage alterations is realized.¹ ² ³ ⁴⁸ ⁵⁰ ⁵² ⁵³ ⁵⁶

Pediatric Patients

Major Depressive Disorder

Oral

Children and adolescents ≥8 years of age: Initially, 10 or 20 mg daily.¹ ³⁹⁰ ³⁹¹ ³⁹² If therapy is initiated at 10 mg daily, should increase dosage after 1 week to 20 mg daily.¹

Manufacturer states that both the initial and target dosage in lower weight children may be 10 mg daily.¹

An increase in dosage to 20 mg daily may be considered after several weeks in lower weight children if insufficient clinical improvement is observed.¹

Obsessive-Compulsive Disorder

Oral

Children and adolescents ≥7 years of age: Initially, 10 mg daily.¹

In adolescents and higher weight children, should increase dosage to 20 mg daily after 2 weeks; additional dosage increases may be considered after several more weeks if insufficient clinical improvement is observed.¹

In lower weight children, dosage increases may be considered after several weeks if insufficient clinical improvement is observed.¹

Usual dosages: 20–60 mg daily for adolescents and higher weight children or 20–30 mg daily for lower weight children.¹

Optimal duration not established.¹ If used for prolonged period, use minimum effective dosage and periodically reassess need for continued therapy.¹ ⁴⁴¹

Adults

Major Depressive Disorder

Oral

As conventional capsules, tablets, or solution: Initially, 20 mg daily (in the morning).¹ May initiate with lower dosage (e.g., 5 mg daily, 20 mg every 2–3 days).² ²¹² If no improvement is apparent after several weeks of therapy with 20 mg daily, an increase in dosage may be considered.¹ ² ¹⁰

Usual dosage: 10–80 mg daily.¹

Delayed-release capsules: 90 mg once weekly, beginning 7 days after the last 20 mg daily dose as conventional capsules, tablets, or solution.¹ ⁴⁰⁰ ⁴⁰¹

If a satisfactory response is not maintained, consider reestablishing daily dosage regimen with conventional capsules, tablets, or solution.¹ ⁴⁰⁰

Optimum duration not established; may require several months of therapy or longer.¹ ²¹⁵ ²¹⁶ ²³³

Obsessive-Compulsive Disorder

Oral

Initially, 20 mg daily (in the morning).¹ If no improvement is apparent after several weeks, dosage may be increased.¹

Usual dosage: 20–60 mg daily; dosages ≤80 mg daily were well tolerated in clinical studies.¹

Optimal duration not established.¹ If used for prolonged period, use minimum effective dosage and periodically reassess need for continued therapy.¹

Premenstrual Dysphoric Disorder

Oral

20 mg once daily given continuously throughout the menstrual cycle or intermittently (i.e., only during the luteal phase, starting 14 days prior to the anticipated onset of menstruation and continuing through the first full day of menses).³⁶⁶

If the intermittent dosing regimen is used, it should be repeated with each new menstrual cycle.³⁶⁶ ⁴⁰⁵

Eating Disorders

Bulimia Nervosa

Oral

60 mg daily (in the morning);¹ dosage may be decreased as necessary to minimize adverse effects.³⁵⁵ Alternatively, dosage may be titrated up to recommended initial dosage over several days.¹

Efficacy was maintained for periods of ≤12 months following 2 months of acute treatment in patients receiving 60 mg daily as conventional fluoxetine capsules.¹ ⁴¹⁰ Most clinicians recommend continuing antidepressant therapy, including fluoxetine, for at least 6–12 months before attempting to discontinue therapy.³⁵⁵ ⁴¹⁰ If used for extended periods, periodically reassess need for continued therapy.¹

Anorexia Nervosa†

Oral

40 mg daily in weight-restored patients has been used.³⁴⁵

Panic Disorder

Oral

Initially, 10 mg daily.¹ ⁴¹⁸ Increase dosage after 1 week to 20 mg daily.¹ ⁴¹⁸ 10–60 mg is effective; 20 mg daily most frequently used.¹ ⁴⁸ Dosages >60 mg daily not systematically evaluated.¹

Optimal duration not established.¹ ⁴³⁵ If used for prolonged period, periodically reassess need for continued therapy.¹

Bipolar Disorder

Monotherapy for Acute Depressive Episodes†

Oral

20–60 mg daily in conjunction with a mood-stabilizing agent (e.g., lithium, lamotrigine).³⁸⁴ ⁴⁰⁴

Combination Therapy for Acute Depressive Episodes

Oral

Fluoxetine/olanzapine (Symbyax): Initially, fluoxetine 25 mg and olanzapine 6 mg (Symbyax 6/25) once daily in the evening.⁴⁴⁸

Fluoxetine 25 mg and olanzapine 3–6 mg (Symbyax 3/25 or Symbyax 6/25) once daily in the evening as initial and maintenance therapy in patients with a predisposition to hypotensive reactions, patients with hepatic impairment, those with a combination of factors that may slow metabolism of the drugs(s) (e.g., female gender, geriatric age, nonsmoking status), or those who may be pharmacodynamically sensitive to olanzapine; when indicated, escalate dosage with caution.⁴⁴⁸

In other patients, increase dosages of fluoxetine/olanzapine according to patient response and tolerance as indicated.⁴⁴⁸ In clinical trials, antidepressive efficacy was demonstrated at olanzapine dosages ranging from 6–12 mg daily and fluoxetine dosages ranging from 25–50 mg daily.⁴⁴⁸ ⁵⁰⁷ ⁵⁰⁸ Dosages >18 mg of olanzapine and 75 mg of fluoxetine not evaluated in clinical studies.¹ ⁴⁴⁸

When used with olanzapine as the single-ingredient components, administer the drugs once daily in the evening, usually initiating therapy with 5 mg of olanzapine and 20 mg of fluoxetine.¹ May adjust dosage within the dosage ranges of 20–50 mg for fluoxetine and 5–12.5 mg for olanzapine.¹ Use an initial dosage of 2.5–5 mg of olanzapine with fluoxetine 20 mg in patients with a predisposition to hypotensive reactions, patients with hepatic impairment, those with a combination of factors that may slow metabolism of the drugs(s) (e.g., female gender, geriatric age, nonsmoking status), or those patients who may be pharmacodynamically sensitive to olanzapine; when indicated, escalate dosage increases with caution.¹

Although the manufacturer states that long-term efficacy (>8 weeks) not established, patients have received the fixed combination ≤24 weeks in clinical trials.⁴⁴⁸ ⁵⁰⁷ ⁵⁰⁸ If used for >8 weeks, periodically reassess need for continued therapy.⁴⁴⁸

Cataplexy†

Oral

20 mg once or twice daily has been used in conjunction with CNS stimulant therapy (e.g., dextroamphetamine, methylphenidate).³⁸⁰

Alcohol Dependence†

Oral

60 mg daily has been used.²⁸⁹

Higher than average antidepressant SSRI dosage apparently is required for reduced alcohol intake; fluoxetine 40 mg daily is comparable to placebo in efficacy.²⁸⁹

Prescribing Limits

Adults

Oral

Conventional capsules, tablets, or solution: Maximum 80 mg daily.¹ ² ³⁶⁶

Special Populations

Hepatic Impairment

Reduce dosage and/or frequency;¹ ² ⁴ ⁵¹ some clinicians recommend a 50% reduction in initial dosage for patients with well-compensated cirrhosis.⁵¹

Carefully individualize dosage in substantial hepatic impairment; adjust based on tolerance and therapeutic response.⁵¹

Renal Impairment

Reduction in dosage and/or frequency not routinely necessary.¹ Supplemental doses after hemodialysis not necessary.⁴ ⁵⁰

Geriatric Patients

Consider reducing dosage and/or frequency.¹

Cautions for FLUoxetine

Contraindications

Concurrent or recent (i.e., within 2 weeks) therapy with an MAO inhibitor.¹ MAO inhibitors are contraindicated within 5 weeks after discontinuance of fluoxetine.² ²⁹⁸ ³⁶⁵ ³⁶⁶ (See Serotonin Syndrome or Neuroleptic Malignant Syndrome-like Reactions under Cautions and also see Interactions.)
Concurrent pimozide therapy.¹
Concurrent thioridazine therapy.¹ Thioridazine is contraindicated within 5 weeks after discontinuance of fluoxetine.¹

Warnings/Precautions

Warnings

Worsening of Depression and Suicidality Risk

Possible worsening of depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior in both adult and pediatric patients with major depressive disorder, whether or not they are taking antidepressants; may persist until clinically important remission occurs.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ ⁵¹² However, suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ ⁵¹⁴

Appropriately monitor and closely observe patients receiving fluoxetine for any reason, particularly during initiation of therapy (i.e., the first few months) and during periods of dosage adjustments.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ ⁵¹² (See Boxed Warning and also see Pediatric Use under Cautions.)

Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and/or mania may be precursors to emerging suicidality.¹ ⁴⁷⁰ ⁴⁷⁶ Consider changing or discontinuing therapy in patients whose depression is persistently worse or in those with emerging suicidality or symptoms that might be precursors to worsening depression or suicidality, particularly if severe, abrupt in onset, or not part of patient’s presenting symptoms.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ If decision is made to discontinue therapy, taper fluoxetine dosage as rapidly as is feasible but consider risks of abrupt discontinuance.¹ ⁴⁷⁰ (See General under Dosage and Administration.)

Prescribe in smallest quantity consistent with good patient management to reduce risk of overdosage.¹ ⁴⁷⁰

Observe these precautions for patients with psychiatric (e.g., major depressive disorder, OCD) or nonpsychiatric disorders.¹ ⁴⁷⁰

Sensitivity Reactions

Allergic Reactions and Rash

Possible anaphylactoid reactions (e.g., bronchospasm, angioedema, laryngospasm, and/or urticaria).¹

Rash and/or urticaria, sometimes associated with systemic manifestations (e.g., fever, leukocytosis, arthralgia, edema, carpal tunnel syndrome, respiratory distress, lymphadenopathy, proteinuria, mild elevation in serum aminotransferase concentrations, vasculitis, lupus-like syndrome) reported; systemic manifestations may be serious.¹ ² ²³⁴ ²⁷⁹

If rash or other possibly allergic manifestations for which an alternative etiology cannot be identified occur, discontinue therapy.¹ ² ²² ²¹⁷

Other Warnings and Precautions

Serotonin Syndrome or Neuroleptic Malignant Syndrome-like Reactions

Potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions reported with SSRIs and SNRIs alone, including fluoxetine, but particularly with concurrent administration of other serotonergic drugs (e.g., 5-HT₁ receptor agonists [triptans]), drugs that impair serotonin metabolism (e.g., MAO inhibitors), or antipsychotics or other dopamine antagonists.¹ ²⁴⁸ ⁴⁹² ⁵¹⁷ ⁵¹⁸ ⁵¹⁹ ⁵²⁶ ⁵²⁹ ⁵³⁰ ⁵³¹ (See Contraindications under Cautions and also see Interactions.)

Symptoms of serotonin syndrome may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile BP, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or GI symptoms (e.g., nausea, vomiting, diarrhea).¹ ⁴⁹² ⁵¹⁷ ⁵¹⁸ ⁵¹⁹ ⁵²⁹ ⁵³⁰ ⁵³¹

Severe serotonin syndrome may resemble NMS, which is characterized by hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuations in vital signs, and mental status changes.¹ ⁵¹⁷ ⁵¹⁸ ⁵¹⁹ ⁵²⁹ ⁵³⁰ ⁵³¹

Monitor patients receiving fluoxetine for the development of serotonin syndrome or NMS-like signs and symptoms.¹ ⁵¹⁷ ⁵²⁹ ⁵³⁰ ⁵³¹ If such signs and symptoms occur, immediately discontinue treatment with fluoxetine and any concurrently administered serotonergic or antidopaminergic agents, including antipsychotic agents, and initiate supportive and symptomatic treatment.¹ ⁵¹⁷ ⁵²⁹ ⁵³⁰

Activation of Mania or Hypomania

Possible hypomania,⁷⁰ ⁸⁶ ²³⁴ mania,⁷⁰ ⁸⁵ ⁸⁶ ⁸⁷ ⁸⁸ ²¹⁷ ²³⁰ ²³⁴ ²⁵⁸ ²⁶⁷ ²⁶⁸ and manic reaction.¹ ⁶ ⁷⁰ ²³⁴ May be more likely in patients with bipolar disorder.⁸⁵ ¹⁹²

Bipolar Disorder

May unmask bipolar disorder.¹ ⁴⁷⁰ (See Activation of Mania or Hypomania under Cautions.)

Screen for risk of bipolar disorder by obtaining detailed psychiatric history (e.g., family history of suicide, bipolar disorder, depression) prior to initiating therapy.¹ ⁴⁷⁰

Seizures

Possible seizures;¹ ² ⁶ ¹⁵ ⁵⁶ ⁸⁹ ⁹¹ use with caution in patients with a history of seizures.¹ ² ⁹¹

Altered Appetite and Weight

Possible anorexia and substantial weight loss, which may be undesirable in underweight or bulimic patients.¹ ² ¹⁵ ⁶⁰ ⁶¹ ⁶³ ⁶⁵ ⁶⁶ ⁶⁷ ⁶⁹ ⁷² ¹²² ¹⁶¹ ¹⁷⁶ Monitor weight change during fluoxetine therapy.¹ (See Pediatric Use under Cautions.)

Abnormal Bleeding

Possible increased risk of bleeding with SSRIs, including fluoxetine, and SNRIs;¹ events ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.¹ ³²⁹ ⁴⁵² ⁴⁵³ ⁴⁵⁴ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁸ Concomitant use of aspirin, NSAIAs, warfarin, or other anticoagulants may increase risk.¹ (See Drugs Affecting Hemostasis and Specific Drugs under Interactions.)

Hyponatremia or SIADH

Treatment with SSRIs, including fluoxetine, and SNRIs may result in hyponatremia;¹ ⁹⁰ ²⁸⁰ ⁵²⁴ ⁵²⁷ ⁵²⁸ ⁵²⁹ ⁵³⁰ ⁵³¹ in many cases, SIADH is apparent cause.¹ ⁹⁰ ²⁸⁰ ²⁸¹ ⁵²⁹ ⁵³⁰ ⁵³¹ Increased risk in patients who are volume depleted, elderly, or taking diuretics.¹ ⁹⁰ ²⁸¹ ⁵²⁴ ⁵²⁹ ⁵³⁰ ⁵³¹ Consider drug discontinuance and initiate appropriate medical intervention in patients with symptomatic hyponatremia.¹ ⁵²⁹ ⁵³⁰ ⁵³¹

Anxiety and Insomnia

Possible dose-related⁴ ⁶⁹ ²¹¹ ²¹⁷ nervousness,¹ ² ¹⁵ ⁶⁰ ⁶¹ ⁶³ ⁶⁵ ⁶⁶ ⁶⁷ ⁷⁰ ⁷¹ ⁷² ¹²² ²³⁴ anxiety,¹ ² ¹⁰ ¹⁵ ⁶¹ ⁶³ ⁶⁵ ⁶⁷ ⁷⁰ ⁷⁵ ¹²² ²³⁴ and insomnia.¹ ² ¹⁰ ¹⁵ ⁶¹ ⁶³ ⁶⁶ ⁶⁷ ⁶⁹ ⁷⁰ ⁷¹ ⁷² ⁷⁵ ¹²² ¹⁷⁶ ²³⁴

Concomitant Illnesses

Limited experience; use with caution in patients with concomitant illnesses affecting metabolism or hemodynamic response.¹

Safety in patients with recent history of MI or those with unstable heart disease not established.¹ ² ³

May alter glycemic control in patients with diabetes mellitus.¹ Hypoglycemia has occurred during fluoxetine therapy and hyperglycemia has developed following discontinuance of drug.¹ Adjust insulin and/or oral antidiabetic agent dosage as necessary when initiating or discontinuing fluoxetine therapy.¹

Mydriasis reported; use with caution in patients with elevated IOP or those at risk of acute narrow-angle glaucoma.¹

Cognitive/Motor Impairment

Potential impairment of judgment, thinking, and motor skills.¹ (See Advice to Patients.)

Long Elimination Half-Life

Because of the long elimination half-lives of fluoxetine and its major active metabolite, norfluoxetine, changes in dosage will take several weeks to be fully reflected in plasma concentrations, which affects dosage titration and withdrawal from treatment.¹ ² ³ ⁴⁸ ⁵⁰ ⁵² ⁵³ ⁵⁶ ²¹⁷ Consider these potential consequences when drug discontinuance is required or when prescribing concurrent drugs that may interact with fluoxetine and norfluoxetine following fluoxetine discontinuance.¹

Withdrawal of Therapy

Withdrawal effects (e.g., dysphoric mood, irritability, agitation, dizziness, sensory disturbances [e.g., paresthesias, such as electric shock sensations], anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania) reported following discontinuance of serotonergic antidepressants, particularly when discontinuance was abrupt.¹ Events generally self-limiting, but serious cases reported.¹

Taper dosage gradually; monitor patients for withdrawal symptoms when discontinuing therapy.¹ If intolerable symptoms occur following dosage reduction or discontinuance, consider reinstituting previously prescribed dosage then resume more gradual dosage reductions.¹

Use of Fixed Combinations

When fluoxetine is used in fixed combination with olanzapine, consider cautions, precautions, contraindications, and interactions associated with each drug.¹ ⁴⁴⁸

Electroconvulsive Therapy (ECT)

Effects of concomitant use with ECT not systematically evaluated.¹ ⁴ Prolonged seizures reported rarely.¹

Specific Populations

Pregnancy

Category C.¹

Possible complications, sometimes severe and requiring prolonged hospitalization, respiratory support, enteral nutrition, and other forms of supportive care, reported in neonates exposed to fluoxetine, other SSRIs, or SNRIs late in the third trimester; may arise immediately upon delivery.¹ ⁴⁶¹ ⁴⁶² ⁴⁸⁰ ⁴⁸⁹ ⁴⁹⁰ ⁴⁹¹

Conflicting findings from available studies evaluating possible risk of persistent pulmonary hypertension of the newborn (PPHN) following in utero exposure to SSRIs; currently unclear whether SSRI use during pregnancy can cause PPHN.¹ ⁶⁰⁰ ⁶⁰² ⁶⁰³ ⁶⁰⁴ ⁶⁰⁵ ⁶⁰⁶ ⁶¹⁰

Consult joint APA and ACOG guidelines (at [Web]) for additional information on management of depression in women prior to conception and during pregnancy, including treatment algorithms.⁶⁰⁰ ⁶⁰⁸

Carefully consider potential risks and benefits of treatment when used during third trimester of pregnancy.¹ ⁴⁸⁰ ⁴⁹⁰ ⁴⁹¹ Consider cautiously tapering dosage during third trimester prior to delivery.¹ ⁴⁸⁰ ⁴⁸¹ ⁴⁸² ⁴⁹¹

Lactation

Distributed into milk; use not recommended.¹

Pediatric Use

Safety and efficacy of fluoxetine not established in children <8 years of age for major depressive disorder and in children <7 years of age for OCD.¹

Safety and efficacy of fluoxetine in fixed combination with olanzapine not established in pediatric patients <18 years of age.¹ ⁴⁴⁸

Decreased appetite and weight loss observed with the use of SSRIs, including fluoxetine; monitor weight and growth regularly in children and adolescents treated with fluoxetine.¹ (See Altered Appetite and Weight under Cautions.)

FDA warns that a greater risk of suicidal thinking or behavior (suicidality) occurred during first few months of antidepressant treatment compared with placebo in children and adolescents with major depressive disorder, OCD, or other psychiatric disorders based on pooled analyses of 24 short-term, placebo-controlled trials of 9 antidepressant drugs (SSRIs and others).¹ ⁴⁷⁰ However, a more recent meta-analysis of 27 placebo-controlled trials of 9 antidepressants (SSRIs, including fluoxetine, and others) in patients <19 years of age with major depressive disorder, OCD, or non-OCD anxiety disorders suggests that the benefits of antidepressant therapy in treating these conditions may outweigh the risks of suicidal behavior or suicidal ideation.⁵¹² No suicides occurred in these pediatric trials.¹ ⁴⁷⁰ ⁵¹²

Carefully consider these findings when assessing potential benefits and risks of fluoxetine in a child or adolescent for any clinical use.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ ⁵¹² (See Boxed Warning and also see Worsening of Depression and Suicidality Risk under Cautions.)

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.¹ However, increased sensitivity cannot be ruled out.¹

SNRIs and SSRIs, including fluoxetine, have been associated with clinically important hyponatremia in geriatric patients, who may be at greater risk for this adverse effect.¹ ⁹⁰ ²⁸¹ ⁵²⁴ ⁵²⁵ ⁵²⁹ ⁵³⁰ ⁵³¹ (See Hyponatremia or SIADH under Cautions.)

In pooled data analyses, a reduced risk of suicidality was observed in adults ≥65 years of age with antidepressant therapy compared with placebo.⁴⁷⁰ ⁴⁷¹ (See Boxed Warning and also see Worsening of Depression and Suicidality Risk under Cautions.)

Hepatic Impairment

Decreased clearance with cirrhosis; use with caution and at reduced dosage and/or frequency.¹ ² ⁵¹ (See Hepatic Impairment under Dosage and Administration.)

Common Adverse Effects

Anxiety, nervousness, insomnia, somnolence, asthenia, tremor, anorexia, nausea, dyspepsia, diarrhea, vasodilation, dry mouth, decreased libido, abnormal ejaculation, impotence, rash, sweating, abnormal dreams, flu syndrome, pharyngitis, sinusitis, yawning.¹ ² ³ ⁵ ⁶ ¹⁰ ⁶¹ ⁶³ ⁷¹ ⁷² ²³⁴

Drug Interactions

Extensively metabolized;¹ ² ³ ⁵¹ ⁵³ inhibits CYP2D6¹ ³⁶⁶ ³⁸⁶ ³⁹⁹ and to much less extent CYP3A4.¹ ³⁶⁶

When used in fixed combination with olanzapine, consider interactions associated with each drug in the fixed combination.⁴⁴⁸

Drugs Associated with Serotonin Syndrome

Potential pharmacologic interaction (potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions) with serotonergic agents.¹ ²⁸³ ²⁹⁹ ³⁰⁰ ³⁰¹ ³⁰³ ⁴⁹² Avoid such use, or use with caution.¹ ²⁰⁰ ²⁹⁹ ⁴⁹² (See Contraindications and see Serotonin Syndrome or Neuroleptic Malignant Syndrome-like Reactions under Cautions.)If serotonin syndrome or NMS occurs, immediately discontinue fluoxetine and any concurrently administered serotonergic agents or antidopaminergic agents and initiate supportive and symptomatic treatment.¹

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP2D6 or CYP3A4: clinically important pharmacokinetic interaction unlikely.¹

Drugs Metabolized by Hepatic Microsomal Enzymes

Substrates of CYP2D6: potential pharmacokinetic interaction.¹ Fluoxetine inhibits CYP2D6 activity; may increase plasma concentrations of drugs metabolized by CYP2D6.¹

Substrates of CYP3A4: clinically important pharmacokinetic interaction unlikely.¹

Drugs Affecting Hemostasis

Potential pharmacologic interaction (increased risk of bleeding) with concomitant use of drugs that affect hemostasis; use with caution.¹ ⁴⁵² ⁴⁸⁷ ⁴⁸⁸ (See Abnormal Bleeding under Cautions.)

Protein-bound Drugs

Fluoxetine displaces and is displaced by protein-bound drugs.¹ ³⁶⁶ Monitor for possible adverse effects if used concomitantly with other protein-bound drugs.²¹⁷

Specific Drugs

Drug	Interaction	Comments
Alcohol	Does not potentiate cognitive and motor effects of alcohol;⁷ ⁹⁹ ¹¹⁴ ²⁰⁶ ²⁰⁷ possible serotonergically-mediated pharmacodynamic interaction in CNS⁹⁹ ¹¹⁵ ¹³⁴ ¹³⁸ ¹⁵⁷ ¹⁷³ ²¹³ ²¹⁴	Concomitant use not recommended¹
Amphetamine	Decreased amphetamine metabolism; potential serotonin syndrome³⁹²
Anticoagulants (e.g., warfarin)	Altered anticoagulant effects, including increased bleeding¹ ³⁶⁶	Carefully monitor patients receiving warfarin when fluoxetine is initiated or discontinued¹ ³⁶⁶
Antidiabetic agents	May alter blood glucose concentrations in patients with diabetes mellitus¹	Adjust insulin and/or antidiabetic dosages as needed when fluoxetine therapy is initiated or discontinued¹
β-Adrenergic blocking agents (e.g., metoprolol, propranolol)	Increased plasma concentrations of β-adrenergic blocking agents metabolized by CYP2D6;³⁶⁵ possible cardiac toxicity³⁶⁵	Renally eliminated β-adrenergic blocking agents (e.g., atenolol) may be a safer choice³⁶⁵
Antidepressants, other SSRIs (e.g., citalopram, escitalopram, fluvoxamine, paroxetine, sertraline) or SNRIs (e.g., desvenlafaxine, duloxetine, milnacipran, venlafaxine)	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹	Concomitant use not recommended¹
Antidepressants, tricyclic (TCAs)	Increased plasma TCA concentrations¹ ³⁶⁶	Observe patient closely for adverse effects.²²⁷ ²⁵⁹ Plasma TCA concentrations may need to be monitored and TCA dosages reduced when fluoxetine is administered concurrently or has been recently discontinued¹
Antipsychotic agents (e.g., clozapine, haloperidol, olanzapine, pimozide, risperidone, thioridazine)	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹ Clozapine: Increased plasma clozapine concentrations¹ ³⁶⁶ ³⁹⁶ Haloperidol: Increased plasma haloperidol concentrations;¹ ³⁶⁶ severe extrapyramidal symptoms have occurred¹¹⁸ Olanzapine: Increase in peak plasma olanzapine concentrations and decreased olanzapine clearance; unlikely to be clinically important¹ ⁵³³ Pimozide: Possible increased risk of QT_c interval prolongation.¹ Bradycardia, altered mental status (e.g., stupor, inability to think clearly), and/or hypersalivation reported rarely with concomitant use⁴⁷⁷ ⁴⁷⁸ ⁴⁷⁹ Risperidone: Possible increased risperidone plasma concentrations; tardive dyskinesia reported³⁶⁸ Thioridazine: Increased plasma thioridazine concentrations;³⁶⁵ serious ventricular arrhythmias and sudden death are possible¹ ³⁶⁵ ³⁶⁶	If serotonin syndrome or NMS occurs, immediately discontinue fluoxetine and any concurrently administered antidopaminergic or serotonergic agents; initiate supportive and symptomatic treatment¹ Clozapine: Use with caution, monitor closely, and consider decreasing clozapine dosage³⁶⁷ Olanzapine: No dosage adjustment necessary¹ Pimozide: Concomitant use contraindicated¹ Thioridazine: Concomitant use is contraindicated; an interval of >5 weeks should elapse between discontinuance of fluoxetine and initiation of thioridazine¹
Benzodiazepines	Increased plasma concentrations of diazepam and alprazolam³⁶⁶	Clinically important interaction possible in geriatric or other susceptible patients²¹⁷
Buspirone	Possible serotonin syndrome³⁰³ ³²⁴
Carbamazepine	Increased plasma concentrations of carbamazepine and its active metabolite;²⁶⁰ ²⁶¹ ²⁶² ²⁶³ ²⁶⁴ carbamazepine toxicity has been reported²⁶⁰ ²⁶¹ ²⁶³	Monitor patient and plasma carbamazepine concentrations closely when fluoxetine therapy is initiated or discontinued and adjust carbamazepine dosage accordingly²⁶² ²⁶³ ²⁶⁴
Diuretics	Increased risk of hyponatremia
Dopamine antagonists	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹	If serotonin syndrome or NMS occurs, immediately discontinue fluoxetine and any concurrently administered antidopaminergic or serotonergic agents; initiate supportive and symptomatic treatment¹
5-HT₁ receptor agonists (triptans)	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹ ⁴⁹²	Observe carefully if used concomitantly, particularly during treatment initiation, dosage increases, or when another serotonergic agent is initiated¹ ³⁶⁶ ⁴⁹² If serotonin syndrome or NMS occurs, immediately discontinue fluoxetine and any concurrently administered antidopaminergic or serotonergic agents; initiate supportive and symptomatic treatment¹
Isoniazid	Potential for serotonin syndrome³⁰⁴ Isoniazid has some MAO-inhibiting activity³⁰⁴
Linezolid	Potentially life-threatening serotonin syndrome or NMS-like reactions¹ ⁴⁹³ ⁴⁹⁴ ⁵¹¹ ⁵¹⁷ ⁵³⁴ ⁵³⁵ ⁵³⁶ ⁵³⁷ ⁵³⁸ ⁵³⁹	Do not use concurrently;⁴⁹³ consider availability of alternative anti-infectives and weigh benefit of linezolid against risk of serotonin syndrome⁴⁹³ If emergency use of linezolid is considered necessary, immediately discontinue fluoxetine; monitor closely for symptoms of CNS toxicity for 5 weeks or until 24 hours after the last linezolid dose, whichever comes first⁴⁹³ If nonemergency use of linezolid is planned, withhold fluoxetine for at least 5 weeks prior to initiating linezolid;⁴⁹³ fluoxetine may be resumed 24 hours after last linezolid dose⁴⁹³ Do not initiate fluoxetine in patients receiving linezolid; when necessary, initiate 24 hours after last linezolid dose⁴⁹³
Lithium	Increased or decreased serum lithium concentrations¹ ¹⁰⁷ ²⁵⁰ ³⁰³ ³²⁴ Lithium toxicity and/or serotonin syndrome has been reported¹ ¹⁰⁷ ²⁵⁰ ³⁰³ ³²⁴	Use with caution ¹ ¹⁰⁷ ³²⁴ and monitor serum lithium concentrations closely¹
MAO inhibitors	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹ ³⁰⁰ ³⁰³ ³²³	Concomitant use is contraindicated¹ Allow at least 5 weeks to elapse between discontinuance of fluoxetine therapy and initiation of MAO inhibitor therapy ¹ ¹²⁰ ²⁹⁵ ²⁹⁸ and at least 2 weeks between discontinuance of MAO inhibitor therapy and initiation of fluoxetine¹ ² ²⁹⁸
NSAIAs (e.g., aspirin)	Increased risk of bleeding¹ ⁴⁵² ⁴⁸⁷ ⁴⁸⁸	Use with caution¹
Pentazocine	Adverse effects resembling serotonin syndrome³⁰³
Phenytoin	Increased plasma phenytoin concentrations and phenytoin toxicity¹
Selegiline	Possible serotonin syndrome³⁰⁰ ³⁰³ ³¹² ³¹³	Avoid concomitant use³¹² ³¹³ Allow at least 5 weeks to elapse between discontinuance of fluoxetine therapy and initiation of selegiline ³¹³ and at least 2 weeks between discontinuance of selegiline and initiation of fluoxetine³¹² ³¹³
Sibutramine (no longer commercially available in US)	Possible serotonin syndrome⁴⁹²	Use with caution⁴⁹²
Stimulants (e.g., methylphenidate)	Potential serotonin syndrome³⁹²	Do not exceed maximum fluoxetine dosage of 20 mg daily³⁹²
Tramadol	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹	Use with caution¹ If serotonin syndrome or NMS occurs, immediately discontinue fluoxetine and any concurrently administered antidopaminergic or serotonergic agents; initiate supportive and symptomatic treatment¹
Trazodone	Increased plasma trazodone concentrations and adverse effects²²⁵ ²⁵⁹	Observe patient closely for adverse effects ²²⁷ ²⁵⁹ and decrease trazodone dosage as necessary¹⁰³ ²²⁵ ²²⁷
Tryptophan and other serotonin precursors	Potentially serious, sometimes fatal serotonin syndrome or NMS-like reactions¹ ² ³ ¹⁰⁰ ³⁰³	Concomitant use not recommended¹
Warfarin	Possible increased risk of bleeding¹	Carefully monitor patients receiving warfarin during initiation and discontinuance of fluoxetine therapy¹

FLUoxetine Pharmacokinetics

Absorption

Bioavailability

Oral bioavailability in humans not fully elucidated,⁴ but at least 60–80% of an oral dose appears to be absorbed.⁴ ⁷

Commercially available conventional and delayed-release capsules, tablets, and oral solution are bioequivalent.¹ ⁴⁹⁵ ⁵⁴²

Onset

Antidepressant effect usually occurs within 1–4 weeks.¹ ² ⁴ ¹⁶ ⁶¹ ⁶⁹ ⁷¹ ⁷²

Maximal therapeutic effect in OCD may take 5 weeks or longer.¹ ⁴⁴¹

Therapeutic effect in PMDD usually occurs in 2–4 weeks.³⁶¹ ³⁶² ³⁶⁴

Food

Food does not appear to affect systemic bioavailability, although it may delay absorption by 1–2 hours.¹

Special Populations

In patients receiving hemodialysis, chronic administration produced steady-state plasma fluoxetine and norfluoxetine (active metabolite) concentrations comparable with those observed in patients with normal renal function.¹

Distribution

Extent

Crosses the blood-brain barrier in humans.¹ ⁵⁴ ⁵⁶

Crosses the placenta in animals.¹ ⁵⁴ ⁵⁶

Distributed into milk in humans.¹ ⁵⁴ ⁵⁶

Plasma Protein Binding

Approximately 95%.¹

Elimination

Metabolism

Extensively metabolized in the liver to norfluoxetine and a number of other unidentified metabolites.¹

Elimination Route

Principally by hepatic metabolism to inactive metabolites excreted by the kidney.¹

Half-life

Elimination half-life of approximately 2–3 days after a single dose and 4–6 days after chronic administration of fluoxetine.¹

Elimination half-life of norfluoxetine is approximately 4–16 days after acute and chronic administration.¹

Special Populations

In patients with chronic liver disease (e.g., cirrhosis), plasma clearances of fluoxetine and norfluoxetine reportedly are decreased and elimination half-lives are increased compared with those of healthy individuals.¹ ⁵¹

In patients with renal impairment, elimination half-lives of fluoxetine and norfluoxetine not substantially altered.³ ⁴ ⁵⁰

Stability

Storage

Oral

Capsules, Conventional and Delayed-release

15–30°C; protect from light.¹

Solution

20–25°C; protect from light.⁵⁴²

Tablets

20–25°C; protect from light.⁴⁹⁵

Actions

Mechanism of action as an antidepressant or as an anti-obsessive agent is unclear but presumed to be linked to potentiation of serotonergic activity in the CNS resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).¹ ² ³ ⁴ ⁷ ⁸ ¹³ ¹⁸ ²¹ ²⁸ ²⁹ ³¹ ³⁷ ⁷⁶ ¹³⁸
Mechanism of action in PMDD not mediated by the drug’s antidepressant or anti-obsessive effects.³⁶¹ ³⁶² ³⁶⁴
Potent and highly selective reuptake inhibitor of serotonin.¹ ² ³ ⁴ ⁷ ⁸ ¹³ ¹⁸ ²¹ ²⁸ ²⁹ ³¹ ³⁷ ⁷⁶ ¹³⁸ Increases synaptic concentrations of serotonin in the CNS but has little or no effect on other neurotransmitters.¹ ² ³ ⁷ ⁸ ¹³ ¹⁸ ²¹ ²⁸ ²⁹ ³¹ ³⁷ ⁷⁶ ¹³⁸ ²⁰¹ ³²⁸ ³²⁹ ³³⁰
No important anticholinergic, α₁-adrenergic blocking, or antihistaminic activity at usual therapeutic dosages.¹ ² ³ ⁷ ⁸ ¹³ ¹⁸ ²¹ ³¹ ²⁰¹
Generally less sedating than most other antidepressants (e.g., TCAs, MAO inhibitors).² ³ ⁴ ⁶ ⁶¹ ¹⁷⁶ ²⁰⁷

Advice to Patients

Importance of providing copy of written patient information (medication guide) each time fluoxetine is dispensed.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ Importance of advising patients to read the patient information before taking fluoxetine and each time the prescription is filled.¹
Risk of suicidality; importance of patients, family, and caregivers being alert to and immediately reporting emergence of suicidality, worsening depression, or unusual changes in behavior, especially during the first few months of therapy or during periods of dosage adjustment.¹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷⁶ (See Worsening of Depression and Suicidality Risk under Cautions.)
Importance of instructing patients not to take fluoxetine with an MAO inhibitor or within 14 days of stopping the MAO inhibitor, and not to take an MAO inhibitor within 5 weeks of stopping fluoxetine therapy.¹
Importance of informing patients of potential risk of serotonin syndrome and neuroleptic malignant syndrome (NMS)-like reactions, particularly with concurrent use of fluoxetine and 5-HT₁ receptor agonists (also called triptans), tramadol, tryptophan, other serotonergic agents, or antipsychotic agents.¹ ⁴⁹² Importance of immediately contacting clinician if signs and symptoms of these syndromes develop (e.g., restlessness, hallucinations, loss of coordination, fast heart beat, increased body temperature, muscle stiffness, increased BP, diarrhea, coma, nausea, vomiting, confusion).¹ ⁴⁹²
Risk of allergic reactions and rash.¹ Importance of advising patients to notify their clinician if they develop a rash or hives.¹ Importance of also advising patients of the signs and symptoms associated with severe allergic reactions (e.g., swelling of the face, eyes, mouth; difficulty breathing) and to seek immediate medical attention if they experience these symptoms.¹
Importance of informing patients that if they receive diuretics, or are otherwise volume-depleted, or are elderly, that they may be at greater risk of developing hyponatremia during fluoxetine therapy.¹
Importance of understanding that full effects of the drug may not be apparent for more than 4–5 weeks following initiation of therapy.¹ ²
Importance of patients being aware that withdrawal effects may occur when stopping fluoxetine, especially with abrupt discontinuance of the drug.¹
Risk of cognitive and motor impairment; importance of avoiding certain activities (e.g., operating machinery, driving a motor vehicle) until effects on the individual are known.¹
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription (e.g., Symbyax, Sarafem) and OTC drugs or herbal supplements and alcohol-containing beverages or products, as well as any concomitant illnesses (e.g., bipolar disorder) or personal or family history of suicidality or bipolar disorder.¹ Importance of also informing clinicians if patients plan to discontinue any medications while receiving fluoxetine therapy.¹
Importance of advising patients about the risk of bleeding or bruising associated with concomitant use of fluoxetine with aspirin or other NSAIAs, warfarin, or other drugs that affect coagulation.¹ Importance of advising patients to inform their clinician if they experience any increased or unusual bruising or bleeding while receiving fluoxetine.¹
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹
Importance of informing patients of other important precautionary information.¹ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

FLUoxetine Hydrochloride
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	10 mg (of fluoxetine)*	FLUoxetine Hydrochloride Capsules
			PROzac Pulvules	Dista
			Sarafem Pulvules	Lilly
		20 mg (of fluoxetine)*	FLUoxetine Hydrochloride Capsules
			PROzac Pulvules	Dista
			Sarafem Pulvules	Lilly
		40 mg (of fluoxetine)*	FLUoxetine Hydrochloride Capsules
			PROzac Pulvules	Dista
	Capsules, delayed-release (containing enteric-coated pellets)	90 mg (of fluoxetine)	PROzac Weekly	Dista
	Solution	20 mg (of fluoxetine) per 5 mL*	Fluoxetine Hydrochloride Oral Solution
	Tablets	10 mg (of fluoxetine)*	FLUoxetine Hydrochloride Tablets
			Sarafem	Warner Chilcott
		15 mg (of fluoxetine)*	Sarafem	Warner Chilcott
		20 mg (of fluoxetine)*	FLUoxetine Hydrochloride Tablets
			Sarafem	Warner Chilcott
		60 mg (of fluoxetine)*	FLUoxetine Hydrochloride Tablets

FLUoxetine Hydrochloride Combinations
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	25 mg (of fluoxetine) with Olanzapine 3 mg	Symbyax (combination)	Lilly
		25 mg (of fluoxetine) with Olanzapine 6 mg	Symbyax	Lilly
		25 mg (of fluoxetine) with Olanzapine 12 mg	Symbyax	Lilly
		50 mg (of fluoxetine) with Olanzapine 6 mg	Symbyax	Lilly
		50 mg (of fluoxetine) with Olanzapine 12 mg	Symbyax	Lilly

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Eli Lilly and Company. Prozac (fluoxetine hydrochloride) Pulvules and delayed-release capsules prescribing information. Indianapolis, IN: 2011 Jun .

2. Dista Products Company. Prozac (fluoxetine hydrochloride) product monograph. Indianapolis, IN; 1987 Dec 30.

3. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32:481-508. http://www.ncbi.nlm.nih.gov/pubmed/2878798?dopt=AbstractPlus

4. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy. 1987; 7:1-15. http://www.ncbi.nlm.nih.gov/pubmed/3554156?dopt=AbstractPlus

5. Asberg M, Eriksson B, Martensson B et al. Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry. 1986; 47(Suppl):23-35. http://www.ncbi.nlm.nih.gov/pubmed/2937776?dopt=AbstractPlus

6. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry. 1985; 46:59-67. http://www.ncbi.nlm.nih.gov/pubmed/3156126?dopt=AbstractPlus

7. Lemberger L, Bergstrom RF, Wolen RL et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985; 46:14-9. http://www.ncbi.nlm.nih.gov/pubmed/3871765?dopt=AbstractPlus

8. Stark P, Fuller RW, Wong DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry. 1985; 46:7- 13. http://www.ncbi.nlm.nih.gov/pubmed/3871767?dopt=AbstractPlus

9. Pi EH, Simpson GM. New antidepressants: a review. Hosp Formul. 1985; 20:580-8.

10. Schatzberg AF, Dessain E, O’Neil P et al. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. J Clin Psychopharmacol. 1987; 7(Suppl):44-9S.

11. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman L, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: The Macmillan Company; 1985:387-445.

12. Muller EE, Locatelli V, Cella S et al. Prolactin-lowering and -releasing drugs: mechanisms of action and therapeutic applications. Drugs. 1983; 25:399-432. http://www.ncbi.nlm.nih.gov/pubmed/6133737?dopt=AbstractPlus

13. Fuller RW, Wong DT. Serotonin reuptake blockers in vitro and in vivo. J Clin Psychopharmacol. 1987; 7(Suppl):36-43S.

14. Yen TT, Wong DT, Bemis KG. Reduction of food consumption and body weight of normal and obese mice by chronic treatment with fluoxetine: a serotonin reuptake inhibitor. Drug Dev Res. 1987; 10:37-45.

15. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985; 46:20-5. http://www.ncbi.nlm.nih.gov/pubmed/3882676?dopt=AbstractPlus

16. Anon. Fluoxetine for depression. Med Lett Drugs Ther. 1988; 30:45-7. http://www.ncbi.nlm.nih.gov/pubmed/3258399?dopt=AbstractPlus

17. Goudie AJ, Thornton EW, Wheeler TJ. Effects of Lilly 110140, a specific inhibitor of 5-hydroxytryptamine uptake, on food intake and on 5-hydroxytryptophan-induced anorexia. Evidence for serotonergic inhibition of feeding. J Pharm Pharmacol. 1976; 28:318-20. http://www.ncbi.nlm.nih.gov/pubmed/6727?dopt=AbstractPlus

18. Wong DT, Bymaster FP, Reid LR et al. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol. 1983; 32:1287-93. http://www.ncbi.nlm.nih.gov/pubmed/6303355?dopt=AbstractPlus

19. Byerley WF, McConnell EJ, McCabe RT et al. Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology. 1988; 94:141-3. http://www.ncbi.nlm.nih.gov/pubmed/2831557?dopt=AbstractPlus

20. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol. 1987; 7(Suppl):24-35S.

21. Fuller RW. Functional consequences of inhibiting serotonin uptake with fluoxetine in rats. In: Ho BT, Schoolar JC, Usdin E, eds. Serotonin in biological psychiatry. New York: Raven Press; 1982:219- 28.

22. Anon. Fluoxetine: an antidepressant with specific serotonin uptake inhibition. Int Drug Ther Newsl. 1988; 23:5-11.

23. Weintraub M, Standish R. Fluoxetine: a specific serotonin uptake inhibitor being studied in depression. Hosp Formul. 1986; 21:758-63.

24. Meltzer HY, Young M, Metz J et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979; 45:165-75. http://www.ncbi.nlm.nih.gov/pubmed/313977?dopt=AbstractPlus

25. Robertson DW, Jones ND, Swartzendruber JK et al. Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor. J Med Chem. 1988; 31:185-9. http://www.ncbi.nlm.nih.gov/pubmed/3257267?dopt=AbstractPlus

26. Robertson DW, Krushinski JH, Fuller RW et al. Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor. J Med Chem. 1988; 31:1412-7. http://www.ncbi.nlm.nih.gov/pubmed/3260286?dopt=AbstractPlus

27. Wong DT, Bymaster FP, Reid LR et al. Inhibition of serotonin uptake by optical isomers of fluoxetine. Drug Dev Res. 1985; 6:397-403.

28. Wong DT, Bymaster FP, Horng JS et al. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylprolylamine. J Pharmacol Exp Ther. 1975; 193:804-11. http://www.ncbi.nlm.nih.gov/pubmed/1151730?dopt=AbstractPlus

29. Fuller RW, Perry KW, Molloy BB. Effect of 3- (p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine. J Pharmacol Exp Ther. 1975; 193:796-803.

30. Wander TJ, Nelson A, Okazaki H et al. Antagonism by antidepressants of serotonin S₁ and S₂ receptors of normal human brain in vitro. Eur J Pharmacol. 1986; 132:115-21. http://www.ncbi.nlm.nih.gov/pubmed/3816971?dopt=AbstractPlus

31. Wong DT, Reid LR, Bymaster FP et al. Chronic effects of fluoxetine, a selective inhibitor of serotonin reuptake, on neurotransmitter receptors. J Neural Transm. 1985; 64:251-69. http://www.ncbi.nlm.nih.gov/pubmed/3003252?dopt=AbstractPlus

32. Sulser F. Mode of action of antidepressant drugs. J Clin Psychiatry. 1983; 44:14-20. http://www.ncbi.nlm.nih.gov/pubmed/6406444?dopt=AbstractPlus

33. Mishra R, Janowsky A, Sulser F. Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: effects of nisoxetine versus fluoxetine. Eur J Pharmacol. 1979; 60:379-82. http://www.ncbi.nlm.nih.gov/pubmed/316774?dopt=AbstractPlus

34. Schmidt MJ, Thornberry JF. Norepinephrine-stimulated cyclic AMP accumulation in brain slices in vitro after serotonin depletion or chronic administration of selective amine reuptake inhibitors. Arch Int Pharmacodyn Ther. 1977; 229:42-51. http://www.ncbi.nlm.nih.gov/pubmed/201222?dopt=AbstractPlus

35. Fuller RW, Snoddy HD. Fluoxetine enantiomers as antagonists of p-chloroamphetamine effects in rats. Pharmacol Biochem Behav. 1986; 24:281-4. http://www.ncbi.nlm.nih.gov/pubmed/3485293?dopt=AbstractPlus

36. Fuller RW, Snoddy HD, Perry KW et al. Importance of duration of drug action in the antagonism of p-chloroamphetamine depletion of brain serotonin—comparison of fluoxetine and chlorimipramine. Biochem Pharmacol. 1978; 27:193-8. http://www.ncbi.nlm.nih.gov/pubmed/623674?dopt=AbstractPlus

37. Wong DT, Horng JS, Bymaster FP et al. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974; 15:471-9. http://www.ncbi.nlm.nih.gov/pubmed/4549929?dopt=AbstractPlus

38. Dumbrille-Ross A, Tang SW. Manipulations of synaptic serotonin: discrepancy of effects on serotonin S₁ and S₂ sites. Life Sci. 1983; 32:2677-84. http://www.ncbi.nlm.nih.gov/pubmed/6602261?dopt=AbstractPlus

39. Wong DT, Bymaster FP. Subsensitivity of serotonin receptors after long-term treatment of rats with fluoxetine. Res Commun Chem Pathol Pharmacol. 1981; 32:41-51. http://www.ncbi.nlm.nih.gov/pubmed/6974884?dopt=AbstractPlus

40. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment: implications for the etiology and therapy of depression. Arch Gen Psychiatry. 1981; 38:1160-80. http://www.ncbi.nlm.nih.gov/pubmed/6271089?dopt=AbstractPlus

41. Bunney WE Jr, Garland BL. Selected aspects of amine and receptor hypotheses of affective illness. J Clin Psychopharmacol. 1981; 1(Suppl):3-11S.

42. Banerjee SP, Kung LS, Riggi SJ et al. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature. 1977; 268:455-6. http://www.ncbi.nlm.nih.gov/pubmed/197419?dopt=AbstractPlus

43. Bergstrom DA, Kellar KJ. Adrenergic and serotonergic receptor binding after chronic desmethylimipramine treatment. J Pharmacol Exp Ther. 1979; 209:256-61. http://www.ncbi.nlm.nih.gov/pubmed/220405?dopt=AbstractPlus

44. Wolfe BB, Harden TK, Sporn JR et al. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther. 1978; 207:446- 57. http://www.ncbi.nlm.nih.gov/pubmed/213556?dopt=AbstractPlus

45. Maggi A, U’Prichard DC, Enna SJ. Differential effects of antidepressant treatment on brain monoaminergic receptors. Eur J Pharmacol. 1980; 61:91-8. http://www.ncbi.nlm.nih.gov/pubmed/6101555?dopt=AbstractPlus

46. Enna SJ, Kendall DA. Interaction of antidepressants with brain neurotransmitter receptors. J Clin Psychopharmacol. 1981; 1(Suppl):12-6S.

47. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980; 210:88-90. http://www.ncbi.nlm.nih.gov/pubmed/6251550?dopt=AbstractPlus

48. Bergstrom RF, Wolen RL, Lemberger L et al. Fluoxetine steady state pharmacokinetics in depressed patients. In: Abstracts of papers presented at American Pharmaceutical Association 133rd annual meeting and exposition. San Francisco, CA: 1986 Mar 16-20; 16:125. Abstract No. P-65.

49. Fuller RW, Snoddy HD, Robertson DW. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav. 1988; 30:715-21. http://www.ncbi.nlm.nih.gov/pubmed/2463643?dopt=AbstractPlus

50. Aronoff GR, Bergstrom RF, Pottratz ST et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther. 1984; 36:138-44. http://www.ncbi.nlm.nih.gov/pubmed/6610522?dopt=AbstractPlus

51. Schenker S, Bergstrom RF, Wolen RL et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1988; 44:353-9. http://www.ncbi.nlm.nih.gov/pubmed/3262026?dopt=AbstractPlus

52. Orsulak PJ, Kenney JT, Debus JR et al. Determination of the antidepressant fluoxetine and its metabolite norfluoxetine in serum by reversed-phase HPLC, with ultraviolet detection. Clin Chem. 1988; 34:1875-8. http://www.ncbi.nlm.nih.gov/pubmed/3262022?dopt=AbstractPlus

53. Lemberger L, Farid NA, Bergstrom RF et al. Fluoxetine, pharmacology and physiologic disposition. Int J Obes. 1987; 11(Suppl 3):157-61. http://www.ncbi.nlm.nih.gov/pubmed/3501991?dopt=AbstractPlus

54. Saletu B, Grunberger J. Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses. J Clin Psychiatry. 1985; 46:45-52. http://www.ncbi.nlm.nih.gov/pubmed/3882681?dopt=AbstractPlus

55. Nash JF, Bopp RJ, Carmichael RH et al. Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection. Clin Chem. 1982; 28:2100-2. http://www.ncbi.nlm.nih.gov/pubmed/6982125?dopt=AbstractPlus

56. Lemberger L, Rowe H, Carmichael R et al. Fluoxetine, a selective serotonin uptake inhibitor. Clin Pharmacol Ther. 1978; 23:421-9. http://www.ncbi.nlm.nih.gov/pubmed/630789?dopt=AbstractPlus

57. Bergstrom RF, van Lier RBL, Lemberger L et al. Absolute bioavailability of fluoxetine in beagle dogs. In: Abstracts of papers presented at American Pharmaceutical Association 133rd annual meeting and exposition. San Francisco, CA: 1986 Mar 16-20; 16:126. Abstract No. P-66.

58. Bergstrom R, Wolen R, Dhahir P et al. Effect of food on the absorption of fluoxetine in normal subjects. In: Abstracts of papers presented at American Pharmaceutical Association Academy of Pharmaceutical Sciences 36th national meeting and 131st APhA annual meeting. Montreal, Canada: 1984 May 5-10; 14:110. Abstract No. 64.

59. Bergstrom RF, Wolen RL, Lemberger L et al. Fluoxetine single dose-multiple dose kinetics. In: Abstracts of papers presented at American Pharmaceutical Association Academy of Pharmaceutical Sciences 39th national meeting. Minneapolis, MN: 1985 Oct 20-24; 15:137. Abstract No. 3.

60. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry. 1984; 45:414-9. http://www.ncbi.nlm.nih.gov/pubmed/6384203?dopt=AbstractPlus

61. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985; 46:53-8. http://www.ncbi.nlm.nih.gov/pubmed/3882682?dopt=AbstractPlus

62. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994:393-444,539-50,771-4.

63. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985; 46:26-31. http://www.ncbi.nlm.nih.gov/pubmed/3882677?dopt=AbstractPlus

64. Wernicke JF, Bremner JD. Fluoxetine effective in the long-term treatment of depression. Br J Clin Pract. 1986; 40(Suppl 46):17-23. http://www.ncbi.nlm.nih.gov/pubmed/3707819?dopt=AbstractPlus

65. Chouinard G. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry. 1985; 46:32-7. http://www.ncbi.nlm.nih.gov/pubmed/3882679?dopt=AbstractPlus

66. Masco HL, Sheetz MS. Double-blind comparison of fluoxetine and amitriptyline in the treatment of major depressive illness. Adv Ther. 1985; 2:275-84.

67. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry. 1985; 46:369-72. http://www.ncbi.nlm.nih.gov/pubmed/3897204?dopt=AbstractPlus

68. Wernicke JF, Dunlop SR, Dornseif BE et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987; 23:164-8. http://www.ncbi.nlm.nih.gov/pubmed/3496625?dopt=AbstractPlus

69. Wernicke JF, Dunlop SR, Dornseif BE et al. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988; 24:183-8. http://www.ncbi.nlm.nih.gov/pubmed/3290940?dopt=AbstractPlus

70. Rickels K, Smith WT, Glaudin V et al. Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry. 1985; 46:38-41. http://www.ncbi.nlm.nih.gov/pubmed/3882680?dopt=AbstractPlus

71. Rickels K, Amsterdam JD, Avallone MF. Fluoxetine in major depression: a controlled study. Curr Ther Res. 1986; 39:559-63.

72. Fabre LF, Crismon L. Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res. 1985; 37:115-23.

73. Holsboer F, Von Bardeleben U, Gerken A et al. Antidepressant efficacy of fluoxetine in a diagnostically homogeneous inpatient population. Br J Clin Pract. 1986; 40(Suppl 46):8-16.

74. Fieve RR, Goodnick PJ, Peselow ED et al. Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry. 1986; 47:560-2. http://www.ncbi.nlm.nih.gov/pubmed/3533909?dopt=AbstractPlus

75. Gorman JM, Liebowitz MR, Fyer AJ et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987; 7:329-32. http://www.ncbi.nlm.nih.gov/pubmed/3500189?dopt=AbstractPlus

76. Fuller RW. Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders. J Clin Psychiatry. 1986; 47(Suppl):4-8. http://www.ncbi.nlm.nih.gov/pubmed/3514585?dopt=AbstractPlus

77. Ferguson JM. Treatment of an anorexia nervosa patient with fluoxetine. Am J Psychiatry. 1987; 144:1239. http://www.ncbi.nlm.nih.gov/pubmed/3498372?dopt=AbstractPlus

78. Wilcox JA. Abuse of fluoxetine by a patient with anorexia nervosa. Am J Psychiatry. 1987; 144:1100. http://www.ncbi.nlm.nih.gov/pubmed/3496803?dopt=AbstractPlus

79. DePaulo JR, Simpson SG. Therapeutic and genetic prospects of an atypical affective disorder. J Clin Psychopharmacol. 1987; 7(Suppl 6):50-4S. http://www.ncbi.nlm.nih.gov/pubmed/3818992?dopt=AbstractPlus

80. Reimherr FW, Wood DR, Byerley B et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull. 1984; 20:70-2. http://www.ncbi.nlm.nih.gov/pubmed/6371874?dopt=AbstractPlus

81. South Wales Antidepressant Drug Trial Group. A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. Int Clin Psychopharmacol. 1988; 3:75-81. http://www.ncbi.nlm.nih.gov/pubmed/3282004?dopt=AbstractPlus

82. Stimmel GL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Commentary 1. Pharmacotherapy. 1987; 7:14.

83. Gelenberg AJ. Fluoxetine: a serotonin-specific, second-generation antidepressant. Commentary 2. Pharmacotherapy. 1987; 7:14-5.

84. Patrias JM. Fluoxetine: a serotonin-specific, second-generation antidepressant. Commentary 2. Pharmacotherapy. 1987; 7:15.

85. Settle EC Jr, Puzzuoli Settle G. A case of mania associated with fluoxetine. Am J Psychiatry. 1984; 141:280-1. http://www.ncbi.nlm.nih.gov/pubmed/6362443?dopt=AbstractPlus

86. Lebegue B. Mania precipitated by fluoxetine. Am J Psychiatry. 1987; 144:1620. http://www.ncbi.nlm.nih.gov/pubmed/3500651?dopt=AbstractPlus

87. Turner SM, Jacob RG, Beidel DC et al. A second case of mania associated with fluoxetine. Am J Psychiatry. 1985; 142:274-5. http://www.ncbi.nlm.nih.gov/pubmed/3871593?dopt=AbstractPlus

88. Chouinard G, Steiner W. A case of mania induced by high-dose fluoxetine treatment. Am J Psychiatry. 1986; 143:686. http://www.ncbi.nlm.nih.gov/pubmed/3485926?dopt=AbstractPlus

89. Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm. 1989; 8:296-8. http://www.ncbi.nlm.nih.gov/pubmed/2785443?dopt=AbstractPlus

90. Hwang AS, Magraw RM. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine. Am J Psychiatry. 1989; 146:399. http://www.ncbi.nlm.nih.gov/pubmed/2784038?dopt=AbstractPlus

91. Ware MR, Stewart RB. Seizures associated with fluoxetine therapy. DICP. 1989; 23:428. http://www.ncbi.nlm.nih.gov/pubmed/2786293?dopt=AbstractPlus

92. Chouinard G, Jones B. No crossover of sensitivity between zimelidine and fluoxetine. Can Med Assoc J. 1984; 131:1190. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1483702&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6238668?dopt=AbstractPlus

93. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry. 1985; 46:42-4. http://www.ncbi.nlm.nih.gov/pubmed/3871766?dopt=AbstractPlus

94. Kalucy RS. Drug-induced weight gain. Drugs. 1980; 19:268-78. http://www.ncbi.nlm.nih.gov/pubmed/6991239?dopt=AbstractPlus

95. Crome P, Ali C. Clinical features and management of self-poisoning with newer antidepressants. Med Toxicol. 1986; 1:411-20. http://www.ncbi.nlm.nih.gov/pubmed/3540518?dopt=AbstractPlus

96. Rumack BH, ed. Poisindex. Fluoxetine. Denver: Micromedex, Inc; 1988 May.

97. Paykel ES, Mueller PS, de la Vergne PM. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry. 1973; 123:501-7. http://www.ncbi.nlm.nih.gov/pubmed/4588039?dopt=AbstractPlus

98. Kahn D, Silver JM, Opler LA. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989; 9:198-202. http://www.ncbi.nlm.nih.gov/pubmed/2738181?dopt=AbstractPlus

99. Lemberger L, Rowe H, Bergstrom RF et al. Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clin Pharmacol Ther. 1985; 37:658-64. http://www.ncbi.nlm.nih.gov/pubmed/3874037?dopt=AbstractPlus

100. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry. 1986; 21:1067-71. http://www.ncbi.nlm.nih.gov/pubmed/3488767?dopt=AbstractPlus

101. Bodkin JA, Teicher MH. Fluoxetine may antagonize the anxiolytic action of buspirone. J Clin Psychopharmacol. 1989; 9:150. http://www.ncbi.nlm.nih.gov/pubmed/2786010?dopt=AbstractPlus

102. Moskowitz H, Burns M. The effects on performance of two antidepressants, alone and in combination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1988; 12:783-92. http://www.ncbi.nlm.nih.gov/pubmed/3265525?dopt=AbstractPlus

103. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry. 1988; 145:1478. http://www.ncbi.nlm.nih.gov/pubmed/3263809?dopt=AbstractPlus

104. Goodnick PJ. Influence of fluoxetine on plasma levels of desipramine. Am J Psychiatry. 1989; 146:552. http://www.ncbi.nlm.nih.gov/pubmed/2784633?dopt=AbstractPlus

105. Rudorfer MV, Potter WZ. Combined fluoxetine and tricyclic antidepressants. Am J Psychiatry. 1989; 146:562-3. http://www.ncbi.nlm.nih.gov/pubmed/2784634?dopt=AbstractPlus

106. Vaughan DA. Combined fluoxetine and tricyclic antidepressants. Am J Psychiatry. 1989; 146:563-4.

107. Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry. 1989; 146:278. http://www.ncbi.nlm.nih.gov/pubmed/2492167?dopt=AbstractPlus

108. Lemberger L, Rowe H, Bosomworth JC et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther. 1988; 43:412-9. http://www.ncbi.nlm.nih.gov/pubmed/3128416?dopt=AbstractPlus

109. Rowe H, Lemberger L, Bergstrom R et al. The effect of co-administration of fluoxetine and diazepam on psychomotor and physiologic responses. Pharmacologist. 1985; 27:196.

110. Turner SM, Jacob RG, Beidel DC et al. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1985; 5:207-12. http://www.ncbi.nlm.nih.gov/pubmed/3894437?dopt=AbstractPlus

111. Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1986; 6:98-101. http://www.ncbi.nlm.nih.gov/pubmed/3517083?dopt=AbstractPlus

112. Primeau F, Fontaine R. Obsessive disorder with self-mutilation: a subgroup responsive to pharmacotherapy. Can J Psychiatry. 1987; 32:699-701. http://www.ncbi.nlm.nih.gov/pubmed/3500773?dopt=AbstractPlus

113. Cole JO, White K, Dugan SJ. The drug therapy of obsessive compulsive disorders. McLean Hosp J. 1987; 12:39-66.

114. Hamilton CA, Sellers EM, Sullivan JT et al. Interactions of fluoxetine (F) and amitriptyline (A) with ethanol. Clin Pharmacol Ther. 1987; 41:231.

115. Grupp LA, Perlanski E, Stewart RB. Attenuation of alcohol intake by a serotonin uptake inhibitor: evidence for mediation through the renin-angiotensin system. Pharmacol Biochem Behav. 1988; 30:823-7. http://www.ncbi.nlm.nih.gov/pubmed/2852370?dopt=AbstractPlus

116. Gosselin RE, Smith RP, Hodge HC. Clinical toxicology of commercial products. 5th ed. Baltimore: The Williams & Wilkins Co; 1984:I8-10.

117. Finnegan KT, Gabiola JM. Fluoxetine overdose. Am J Psychiatry. 1988; 145:1604. http://www.ncbi.nlm.nih.gov/pubmed/3264119?dopt=AbstractPlus

118. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry. 1989; 146:399-400. http://www.ncbi.nlm.nih.gov/pubmed/2784039?dopt=AbstractPlus

119. Bell IR, Cole JO. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol. 1988; 8:447-8. http://www.ncbi.nlm.nih.gov/pubmed/3266222?dopt=AbstractPlus

120. Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet. 1988; 2:850-1. http://www.ncbi.nlm.nih.gov/pubmed/2902292?dopt=AbstractPlus

121. Pope HG Jr, McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry. 1988; 145:1292-4. http://www.ncbi.nlm.nih.gov/pubmed/3262313?dopt=AbstractPlus

122. Debus JR, Rush AJ, Himmel C et al. Fluoxetine versus trazodone in the treatment of outpatients with major depression. J Clin Psychiatry. 1988; 49:422-6. http://www.ncbi.nlm.nih.gov/pubmed/3053668?dopt=AbstractPlus

123. Ferguson JM. Fluoxetine-induced weight loss in overweight, nondepressed subjects. Am J Psychiatry. 1986; 143:1496. http://www.ncbi.nlm.nih.gov/pubmed/3535547?dopt=AbstractPlus

124. Rockman GE, Amit Z, Brown ZW et al. An investigation of the mechanisms of action of 5- hydroxytryptamine in the suppression of ethanol intake. Neuropharmacology. 1982; 21:341-7. http://www.ncbi.nlm.nih.gov/pubmed/7088267?dopt=AbstractPlus

125. Van Woert MH, Magnussen I, Rosenbaum D et al. Fluoxetine in the treatment of intention myoclonus. Clin Neuropharmacol. 1983; 6:49-54. http://www.ncbi.nlm.nih.gov/pubmed/6189599?dopt=AbstractPlus

126. Chung E. Cerebellar cyclic GMP in p,p′-DDT myoclonus: effects of antimyoclonic agents. Res Commun Chem Pathol Pharmacol. 1983; 40:87-98. http://www.ncbi.nlm.nih.gov/pubmed/6306746?dopt=AbstractPlus

127. Zabik JE, Roache JD, Sidor R et al. The effects of fluoxetine on ethanol preference in the rat. Pharmacologist. 1982; 24:204.

128. Murphy JM, Gatto GJ, Waller MB et al. Effects of scheduled access on ethanol intake by the alcohol-preferring (P) line of rats. Alcohol. 1986; 3:331-6. http://www.ncbi.nlm.nih.gov/pubmed/3778650?dopt=AbstractPlus

129. Langdon N, Shindler J, Parkes JD et al. Fluoxetine in the treatment of cataplexy. Sleep. 1986; 9:371-3. http://www.ncbi.nlm.nih.gov/pubmed/3509809?dopt=AbstractPlus

130. Slater IH, Jones GT, Moore RA. Inhibition of REM sleep by fluoxetine, a specific inhibitor of serotonin uptake. Neuropharmacology. 1978; 17:383-9. http://www.ncbi.nlm.nih.gov/pubmed/209365?dopt=AbstractPlus

131. Pastel RH, Fernstrom JD. Short-term effects of fluoxetine and trifluoromethylphenylpiperazine on electroencephalographic sleep in the rat. Brain Res. 1987; 436:92-102. http://www.ncbi.nlm.nih.gov/pubmed/3500757?dopt=AbstractPlus

132. Nicholson AN, Pascoe PA. Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology. 1988; 27:597-602. http://www.ncbi.nlm.nih.gov/pubmed/3262203?dopt=AbstractPlus

133. Kupfer DJ, Spiker DG, Coble PA et al. Sleep and treatment prediction in endogenous depression. Am J Psychiatry. 1981; 138:429-34. http://www.ncbi.nlm.nih.gov/pubmed/7212100?dopt=AbstractPlus

134. Linnoila M, Eckardt M, Durcan M et al. Interactions of serotonin with ethanol: clinical and animal studies. Psychopharmacol Bull. 1987; 23:452-7. http://www.ncbi.nlm.nih.gov/pubmed/3324152?dopt=AbstractPlus

135. Fuller RW, Perry KW, Molloy BB. Effect of an uptake inhibitor on serotonin metabolism in rat brain: studies with 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylprop ylamine (Lilly 110140). Life Sci. 1974; 15:1161-71. http://www.ncbi.nlm.nih.gov/pubmed/4550008?dopt=AbstractPlus

136. Bymaster FP, Wong DT. Effect of Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine on synthesis of³H serotonin from³H-tryptophan in rat brain. Pharmacologist. 1974; 16:244.

137. Chung Hwang E, Magnussen I, Van Woert MH. Effects of chronic fluoxetine administration on serotonin metabolism. Res Commun Chem Path Pharmacol. 1980; 29:79-98.

138. Guan XM, McBride WJ. Fluoxetine increases the extracellular levels of serotonin in the nucleus accumbens. Brain Res Bull. 1988; 21:43-6. http://www.ncbi.nlm.nih.gov/pubmed/2464422?dopt=AbstractPlus

139. Peroutka SJ, Snyder SH. Regulation of serotonin₂ (5-HT₂) receptors labeled with [³H] spiroperidol by chronic treatment with the antidepressant amitriptyline. J Pharmacol Exp Ther. 1980; 215:582-7. http://www.ncbi.nlm.nih.gov/pubmed/6255132?dopt=AbstractPlus

140. Garver DL, Davis JM. Minireview: biogenic amine hypotheses of affective disorders. Life Sci. 1979; 24:383-94. http://www.ncbi.nlm.nih.gov/pubmed/372718?dopt=AbstractPlus

141. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965; 122:509-22. http://www.ncbi.nlm.nih.gov/pubmed/5319766?dopt=AbstractPlus

142. Kendall DA, Duman R, Slopis J et al. Influence of adrenocorticotropin hormone and yohimbine on antidepressant-induced declines in rat brain neurotransmitter receptor binding and function. J Pharmacol Exp Ther. 1982; 222:566-71. http://www.ncbi.nlm.nih.gov/pubmed/6286924?dopt=AbstractPlus

143. Messing RB, Phebus L, Fisher LA et al. Analgesic effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake. Psychopharmacol Commun. 1975; 1:511-21. http://www.ncbi.nlm.nih.gov/pubmed/132683?dopt=AbstractPlus

144. Lin MT, Chandra A, Chi ML et al. Effects of increasing serotonergic receptor activity in brain on analgesic activity in rats. Exp Neurol. 1980; 68:548- 54. http://www.ncbi.nlm.nih.gov/pubmed/6966578?dopt=AbstractPlus

145. Gebhart GF, Lorens SA. Attenuation of pethidine-induced antinociception by zimelidine, an inhibitor of 5-hydroxytryptamine reuptake. Br J Pharmacol. 1980; 70:411-4. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2044343&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6449224?dopt=AbstractPlus

146. Hynes MD, Fuller RW. The effect of fluoxetine on morphine analgesia, respiratory depression, and lethality. Drug Dev Res. 1982; 2:33-42.

147. Sugrue MF, McIndewar I. Effect of blockade of 5-hydroxytryptamine re-uptake on drug-induced antinociception in the rat. J Pharm Pharmacol. 1976; 28:447-8. http://www.ncbi.nlm.nih.gov/pubmed/6756?dopt=AbstractPlus

148. Larson AA, Takemori AE. Effect of fluoxetine hydrochloride (Lilly 110140), a specific inhibitor of serotonin uptake, on morphine analgesia and the development of tolerance. Life Sci. 1977; 21:1807-12. http://www.ncbi.nlm.nih.gov/pubmed/604708?dopt=AbstractPlus

149. Malec D, Langwinski R. Effect of quipazine and fluoxetine on analgesic-induced catalepsy and antinociception in the rat. J Pharm Pharmacol. 1980; 32:71-3. http://www.ncbi.nlm.nih.gov/pubmed/6102137?dopt=AbstractPlus

150. Hynes MD, Lochner MA, Bemis KG et al. Fluoxetine, a selective inhibitor of serotonin uptake, potentiates morphine analgesia without altering its discriminative stimulus properties or affinity for opioid receptors. Life Sci. 1985; 36:2317-23. http://www.ncbi.nlm.nih.gov/pubmed/2989631?dopt=AbstractPlus

151. Lee RL, Spencer PSJ. The effect of clomipramine and other amine-uptake inhibitors on morphine analgesia in laboratory animals. Postgrad Med J. 1977; 53(Suppl 4):53-61. http://www.ncbi.nlm.nih.gov/pubmed/600899?dopt=AbstractPlus

152. Hwang AS, Wilcox GL. Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987; 28:343-55. http://www.ncbi.nlm.nih.gov/pubmed/3494977?dopt=AbstractPlus

153. Feldman RS, Smith WC. Chlordiazepoxide-fluoxetine interactions on food intake in free-feeding rats. Pharmacol Biochem Behav. 1978; 8:749-52. http://www.ncbi.nlm.nih.gov/pubmed/308664?dopt=AbstractPlus

154. Rowland N, Antelman SM, Kocan D. Differences among “serotonergic” anorectics in a cross-tolerance paradigm: do they all act on serotonin systems? Eur J Pharmacol. 1982; 81:57-66.

155. Leander JD. Fluoxetine suppresses palatability-induced ingestion. Psychopharmacology (Berl). 1987; 91:285-7. http://www.ncbi.nlm.nih.gov/pubmed/3104951?dopt=AbstractPlus

156. Wurtman JJ, Wurtman RJ. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science. 1977; 198:1178-80. http://www.ncbi.nlm.nih.gov/pubmed/929195?dopt=AbstractPlus

157. McBride WJ, Murphy JM, Lumeng L et al. Effects of Ro 15-4513, fluoxetine and desipramine on the intake of ethanol, water and food by the alcohol-preferring (P) and -nonpreferring (NP) lines of rats. Pharmacol Biochem Behav. 1988; 30:1045-50. http://www.ncbi.nlm.nih.gov/pubmed/3265788?dopt=AbstractPlus

158. Angel I, Taranger MA, Claustre T et al. Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and³H-mazindol binding in vitro. Life Sci. 1988; 43:651-8. http://www.ncbi.nlm.nih.gov/pubmed/3261828?dopt=AbstractPlus

159. Kim SH, Wurtman RJ. Selective effects of CGS 10686B, dl-fenfluramine or fluoxetine on nutrient selection. Physiol Behav. 1988; 42:319-22. http://www.ncbi.nlm.nih.gov/pubmed/2838855?dopt=AbstractPlus

160. Weiss GF, Papadakos P, Knudson K et al. Medial hypothalamic serotonin: effects on deprivation and norepinephrine-induced eating. Pharmacol Biochem Behav. 1986; 25:1223-30. http://www.ncbi.nlm.nih.gov/pubmed/3027720?dopt=AbstractPlus

161. Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull. 1988; 24:220-3. http://www.ncbi.nlm.nih.gov/pubmed/3264922?dopt=AbstractPlus

162. Zerbe RL. Safety of fluoxetine in the treatment of obesity. Int J Obes. 1987; 11:191-9. http://www.ncbi.nlm.nih.gov/pubmed/3501995?dopt=AbstractPlus

163. Simpson RJ, Lawton DJ, Watt MH et al. Effect of zimelidine, a new antidepressant, on appetite and body weight. Br J Clin Pharmacol. 1981; 11:96-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1401706&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6452151?dopt=AbstractPlus

164. Bernstein JG. Induction of obesity by psychotropic drugs. Ann NY Acad Sci. 1987; 499:203-15. http://www.ncbi.nlm.nih.gov/pubmed/2886102?dopt=AbstractPlus

165. Clemens JA, Sawyer BD, Cerimele B. Further evidence that serotonin is a neurotransmitter involved in the control of prolactin secretion. Endocrinology. 1977; 100:692-8. http://www.ncbi.nlm.nih.gov/pubmed/401022?dopt=AbstractPlus

166. Morgan WW, Herbert DC. Elevation of serum prolactin levels after the inhibition of serotonin uptake. Endocrinology. 1978; 103:1016-22. http://www.ncbi.nlm.nih.gov/pubmed/311282?dopt=AbstractPlus

167. Wurtman JJ, Wurtman RJ. Fenfluramine and other serotonergic drugs depress food intake and carbohydrate consumption while sparing protein consumption. Curr Med Res Opin. 1979; 6(Suppl 1):28-33.

168. Hart JC, Leander JD. Reduction of palatability-induced fluid consumption by serotonergic uptake inhibition with fluoxetine. Pharmacologist. 1984; 26:183.

169. Blundell JE. Serotonin and appetite. Neuropharmacology. 1984; 23:1537-51. http://www.ncbi.nlm.nih.gov/pubmed/6152027?dopt=AbstractPlus

170. Burket RC, Hodgin JD. Fluoxetine treatment of a depressed patient susceptible to malignant hyperthermia. Am J Psychiatry. 1989; 146:680. http://www.ncbi.nlm.nih.gov/pubmed/2785349?dopt=AbstractPlus

171. Awad AG. New antidepressants—the serotonin reuptake inhibitors. Psychiatr J Univ Ottawa. 1987; 12:31-4.

172. Naranjo CA, Sellers EM, Roach CA et al. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984; 35:374-81. http://www.ncbi.nlm.nih.gov/pubmed/6230195?dopt=AbstractPlus

173. Naranjo CA, Sellers EM, Sullivan JT et al. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987; 41:266-74. http://www.ncbi.nlm.nih.gov/pubmed/3469057?dopt=AbstractPlus

174. Riddle MA, Leckman JF, Hardin MT et al. Fluoxetine treatment of obsessions and compulsions in patients with Tourette’s syndrome. Am J Psychiatry. 1988; 145:1173-4. http://www.ncbi.nlm.nih.gov/pubmed/3046386?dopt=AbstractPlus

175. Hollander E, Papp L, Campeas R et al. More on self mutilation and obsessive compulsive disorder. Can J Psychiatry. 1988; 33:675. http://www.ncbi.nlm.nih.gov/pubmed/3058294?dopt=AbstractPlus

176. Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Br J Psychiatry. 1987; 150:653-5. http://www.ncbi.nlm.nih.gov/pubmed/3307982?dopt=AbstractPlus

177. Brady K, Zarzar M, Lydiard RB. Fluoxetine in panic disorder patients with imipramine-associated weight gain. J Clin Psychopharmacol. 1989; 9:66-7. http://www.ncbi.nlm.nih.gov/pubmed/2785123?dopt=AbstractPlus

178. Kelly MW, Perry PJ, Holstad SG et al. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit. 1989; 11:165-70. http://www.ncbi.nlm.nih.gov/pubmed/2785723?dopt=AbstractPlus

179. Pohland RC, Byrd TK, Hamilton M et al. Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol. 1989; 98:198-205. http://www.ncbi.nlm.nih.gov/pubmed/2785300?dopt=AbstractPlus

180. Graham PM, Ilett KF. Danger of MAOI therapy after fluoxetine withdrawal. Lancet. 1988; 2:1255-6. http://www.ncbi.nlm.nih.gov/pubmed/2903989?dopt=AbstractPlus

181. Lin MT. Effects of specific inhibitors of 5- hydroxytryptamine uptake on thermoregulation in rats. J Physiol. 1978; 284:147-54. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1282813&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/310457?dopt=AbstractPlus

182. Kleven MS, Dwoskin LP, Sparber SB. Pharmacological evidence for the existence of multiple functional pools of brain serotonin: analysis of brain perfusate from conscious rats. J Neurochem. 1983; 41:1143-9. http://www.ncbi.nlm.nih.gov/pubmed/6194257?dopt=AbstractPlus

183. Chung Hwang E, Van Woert MH. p,p′-DDT-induced myoclonus: serotonin and alpha noradrenergic interaction. Res Commun Chem Pathol Pharmacol. 1979; 23:257-66. http://www.ncbi.nlm.nih.gov/pubmed/37558?dopt=AbstractPlus

184. Chung Hwang E, Van Woert MH. p,p′-DDT-induced neurotoxic syndrome: experimental myoclonus. Neurology. 1978; 28:1020-5. http://www.ncbi.nlm.nih.gov/pubmed/311446?dopt=AbstractPlus

185. Krulich L. The effect of a serotonin uptake inhibitor (Lilly 110140) on the secretion of prolactin in the rat. Life Sci. 1975; 17:1141-4. http://www.ncbi.nlm.nih.gov/pubmed/1081634?dopt=AbstractPlus

186. Fuller RW. Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology. 1981; 32:118-27. http://www.ncbi.nlm.nih.gov/pubmed/7010191?dopt=AbstractPlus

187. Fuller RW, Snoddy HD, Molloy BB. Pharmacologic evidence for a serotonin neural pathway involved in hypothalamus-pituitary-adrenal function in rats. Life Sci. 1976; 19:337-46. http://www.ncbi.nlm.nih.gov/pubmed/183074?dopt=AbstractPlus

188. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res. 1983; 280:176-9. http://www.ncbi.nlm.nih.gov/pubmed/6317143?dopt=AbstractPlus

189. Petraglia F, Facchinetti F, Martignoni E et al. Serotonergic agonists increase plasma levels of β-endorphin and β-lipotropin in humans. J Clin Endocrinol Metab. 1984; 59:1138-42. http://www.ncbi.nlm.nih.gov/pubmed/6092410?dopt=AbstractPlus

190. Wold JS, Joost RR, Griffing WJ et al. Phospholipid accumulation in rats produced by fluoxetine and chlorphentermine. Toxicol Appl Pharmacol. 1976; 37:118-9.

191. Fuller RW, Rathbun RC, Parli CJ. Inhibition of drug metabolism by fluoxetine. Res Commun Chem Pathol Pharmacol. 1976; 13:353-6. http://www.ncbi.nlm.nih.gov/pubmed/943818?dopt=AbstractPlus

192. Bunney WE Jr, Goodwin FK, Murphy DL et al. The “switch process” in manic-depressive illness. II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry. 1974; 27:304-9.

193. Modell JG. Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration. J Clin Psychopharmacol. 1989; 9:63-5. http://www.ncbi.nlm.nih.gov/pubmed/2785122?dopt=AbstractPlus

194. Lloyd KG, Thuret F, Pilc A. Upregulation of γ-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther. 1985; 235:191-9. http://www.ncbi.nlm.nih.gov/pubmed/2995646?dopt=AbstractPlus

195. Ferguson JM, Feighner JP. Fluoxetine-induced weight loss in overweight non-depressed humans. Int J Obes. 1987; 11(Suppl 3):163-70. http://www.ncbi.nlm.nih.gov/pubmed/3501992?dopt=AbstractPlus

196. Corne SJ, Pickering RW, Warner BT. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol Chemother. 1963; 20:106-20. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1703746&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/14023050?dopt=AbstractPlus

197. Babcock DA, Narver EL, Dement WC et al. Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav. 1976; 5:599-602. http://www.ncbi.nlm.nih.gov/pubmed/1035802?dopt=AbstractPlus

198. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman L, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: The Macmillan Company; 1985:605-38.

199. Bowsher DJ, Rowe H, Norid NA et al. Pressor responses to tyramine and norepinephrine after subchronic administration of fluoxetine to man. Life Sci. 1988; 42:2569-75. http://www.ncbi.nlm.nih.gov/pubmed/3260321?dopt=AbstractPlus

200. Kline SS, Mauro LS, Scala-Barnett DM et al. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm. 1989; 8:510-4. http://www.ncbi.nlm.nih.gov/pubmed/2568897?dopt=AbstractPlus

201. Hall H, Sallemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol (Copenh). 1984; 54:379-84. http://www.ncbi.nlm.nih.gov/pubmed/6464782?dopt=AbstractPlus

202. Soliman KF, Gabriel NN. Effect of biogenic amines reuptake inhibition on ethanol induced hypothermia. Gen Pharmacol. 1983; 14:461-3. http://www.ncbi.nlm.nih.gov/pubmed/6618150?dopt=AbstractPlus

203. Fuller RW, Baker JC. Further evidence for serotonin involvement in thermoregulation following morphine administration from studies with an inhibitor of serotonin uptake. Res Comm Chem Pathol Pharmacol. 1974; 8:715-8.

204. Peters JR, Grahame-Smith DG. Human platelet 5HT receptors: characterisation and functional association. Eur J Pharmacol. 1980; 68:243-56. http://www.ncbi.nlm.nih.gov/pubmed/7202490?dopt=AbstractPlus

205. Montgomery SA, Gabriel R, James D et al. Hypersensitivity to zimelidine without cross reactivity to fluoxetine. Int Clin Psychopharmacol. 1989; 4(Suppl 1):27-9. http://www.ncbi.nlm.nih.gov/pubmed/2521657?dopt=AbstractPlus

206. Schaffler K. Study on performance and alcohol interaction with the antidepressant fluoxetine. Int Clin Psychopharmacol. 1989; 4(Suppl 1):15-20. http://www.ncbi.nlm.nih.gov/pubmed/2783698?dopt=AbstractPlus

207. Allen D, Lader M. Interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Int Clin Psychopharmacol. 1989; 4(Suppl 1):7-14. http://www.ncbi.nlm.nih.gov/pubmed/2783702?dopt=AbstractPlus

208. von Bardeleben U, Steiger A, Gerken A et al. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol. 1989; 4(Suppl 1):1-5. http://www.ncbi.nlm.nih.gov/pubmed/2536765?dopt=AbstractPlus

209. von Bardeleben U, Holsboer F, Gerken A et al. Mood elevating effect of fluoxetine in a diagnostically homogeneous inpatient population with major depressive disorder. Int Clin Psychopharmacol. 1989; 4(Suppl 1):31-5. http://www.ncbi.nlm.nih.gov/pubmed/2644337?dopt=AbstractPlus

210. Poelinger W, Haber H. Fluoxetine 40mg vs maprotiline 75mg in the treatment of out-patients with depressive disorders. Int Clin Psychopharmacol. 1989; 4(Suppl 1):47-50. http://www.ncbi.nlm.nih.gov/pubmed/2644340?dopt=AbstractPlus

211. Montgomery SA. The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol. 1989; 4(Suppl 1):113-9. http://www.ncbi.nlm.nih.gov/pubmed/2644336?dopt=AbstractPlus

212. Wernicke JF, Bosomworth JC, Ashbrook E. Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol. 1989; 4(Suppl 1):63-7. http://www.ncbi.nlm.nih.gov/pubmed/2644341?dopt=AbstractPlus

213. Murphy JM, Waller MB, Gatto GJ et al. Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats. Alcohol. 1988; 5:283-6. http://www.ncbi.nlm.nih.gov/pubmed/3265874?dopt=AbstractPlus

214. Murphy JM, Waller MB, Gatto GJ et al. Monoamine uptake inhibitors attenuate ethanol intake in alcohol-preferring (P) rats. Alcohol. 1985; 2:349-52. http://www.ncbi.nlm.nih.gov/pubmed/3925968?dopt=AbstractPlus

215. Cooper AJ. Guide to the long-term drug treatment of major affective disorder: a review. Psychiatr J Univ Ottawa. 1988; 13:144-8.

216. Anon. How long should antidepressive treatment continue? Drug Ther Bull. 1988; 26:79-80.

217. Reviewers’ comments (personal observations).

218. Vogel GW, Vogel F, McAbee RS et al. Improvement of depression by REM sleep deprivation: new findings and a theory. Arch Gen Psychiatry. 1980; 37:247-53. http://www.ncbi.nlm.nih.gov/pubmed/7362414?dopt=AbstractPlus

219. Naranjo CA, Sellers EM, Sanhueza P et al. The serotonin uptake inhibitor, fluoxetine, reduced alcohol consumption in problem drinkers. Psychopharmacology. 1988; 96(Suppl):311. http://www.ncbi.nlm.nih.gov/pubmed/2906152?dopt=AbstractPlus

220. Freeman CPL, Hampson M. Fluoxetine as a treatment for bulimia nervosa. Int J Obes. 1987; 11(Suppl 3):171-7. http://www.ncbi.nlm.nih.gov/pubmed/3501993?dopt=AbstractPlus

221. Jenike MA, Buttolph L, Baer L et al. An open trial of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1989; 146:909-11. http://www.ncbi.nlm.nih.gov/pubmed/2787123?dopt=AbstractPlus

222. USPDI: drug information for the health care professional. Johnson KW, ed. 19th ed. Williston, VT: Micromedex; 1999:1503-7.

223. Kline MD. Fluoxetine and anorgasmia. Am J Psychiatry. 1989; 146:804-5. http://www.ncbi.nlm.nih.gov/pubmed/2786344?dopt=AbstractPlus

224. Renyi L. The effect of selective 5-hydroxytryptamine uptake inhibitors on 5-methoxy-N,N-dimethyltryptamine-induced ejaculation in the rat. Br J Pharmacol. 1986; 87:639-48. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1916791&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2939912?dopt=AbstractPlus

225. Aranow RB, Hudson JI, Pope HG Jr et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry. 1989; 146:911-3. http://www.ncbi.nlm.nih.gov/pubmed/2787124?dopt=AbstractPlus

226. Levine R, Hoffman JS, Knepple ED et al. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. J Clin Psychopharmacol. 1989; 9:281-3. http://www.ncbi.nlm.nih.gov/pubmed/2504781?dopt=AbstractPlus

227. Downs JM, Downs AD, Rosenthal TL et al. Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. J Clin Psychiatry. 1989; 50:226-7. http://www.ncbi.nlm.nih.gov/pubmed/2785987?dopt=AbstractPlus

228. Kinney-Parker JL, Smith D, Ingle SF. Fluoxetine and weight: something lost and something gained? Clin Pharm. 1989; 8:727-33.

229. Mitchell JE, Pyle RL, Eckert ED et al. Response to alternative antidepressants in imipramine nonresponders with bulimia nervosa. J Clin Psychopharmacol. 1989; 9:291-3. http://www.ncbi.nlm.nih.gov/pubmed/2671061?dopt=AbstractPlus

230. Nakra BRS, Szwabo P, Grossberg GT. Mania induced by fluoxetine. Am J Psychiatry. 1989; 146:1515-6. http://www.ncbi.nlm.nih.gov/pubmed/2817129?dopt=AbstractPlus

231. McElroy SL, Keck PE Jr, Pope HG Jr et al. Pharmacological treatment of kleptomania and bulimia nervosa. J Clin Psychopharmacol. 1989; 9:358-60. http://www.ncbi.nlm.nih.gov/pubmed/2677062?dopt=AbstractPlus

232. Clifton PG, Barnfield AMC, Philcox L. A behavioral profile of fluoxetine-induced anorexia. Psychopharmacology. 1989; 97:89-95. http://www.ncbi.nlm.nih.gov/pubmed/2496433?dopt=AbstractPlus

233. Montgomery SA, Dufour H, Brion S et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988; 153(Suppl 3):69-76.

234. Cooper GL. The safety of fluoxetine—an update. Br J Psychiatry. 1988; 153(Suppl 3):77-86.

235. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990; 147:207-10. http://www.ncbi.nlm.nih.gov/pubmed/2301661?dopt=AbstractPlus

236. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. N Engl J Med. 1991; 324:420. http://www.ncbi.nlm.nih.gov/pubmed/1987466?dopt=AbstractPlus

237. Anon. In defense of fluoxetine. Int Drug Ther Newsl. 1990; 25:29-30.

238. Teicher MH, Glod CA, Cole JO. Discussion of fluoxetine and suicidal tendencies. Am J Psychiatry. 1990; 147:1572. http://www.ncbi.nlm.nih.gov/pubmed/2221177?dopt=AbstractPlus

239. Dista Products Company. Dear doctor letter regarding possible relationship between therapy with Prozac and suicidal ideation. Indianapolis, IN: Eli Lilly and Company; 1990 Sep 7.

240. Miller RA. Discussion of fluoxetine and suicidal tendencies. Am J Psychiatry. 1990; 147:1571. http://www.ncbi.nlm.nih.gov/pubmed/2221176?dopt=AbstractPlus

241. Tollefson GD. Fluoxetine and suicidal ideation. Am J Psychiatry. 1990; 147:1691-2. http://www.ncbi.nlm.nih.gov/pubmed/2244652?dopt=AbstractPlus

242. Teicher MH, Glod CA, Cole JO. Fluoxetine and suicidal ideation. Am J Psychiatry. 1990; 147:1692-3.

243. Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol. 1988; 8:347-9. http://www.ncbi.nlm.nih.gov/pubmed/3183073?dopt=AbstractPlus

244. Anon. Fluoxetine (Prozac) revisited. Med Lett Drugs Ther. 1990; 32:83-5. http://www.ncbi.nlm.nih.gov/pubmed/2392089?dopt=AbstractPlus

245. Jones WA. More on “liquid” fluoxetine. Int Drug Ther Newsl. 1990; 25:32.

246. McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry. 1990; 51:383-4. http://www.ncbi.nlm.nih.gov/pubmed/2211550?dopt=AbstractPlus

247. Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine. J Clin Psychiatry. 1990; 51:487. http://www.ncbi.nlm.nih.gov/pubmed/2228987?dopt=AbstractPlus

248. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry. 1990; 28:518-21. http://www.ncbi.nlm.nih.gov/pubmed/2223920?dopt=AbstractPlus

249. Jenike MA. Severe hair loss associated with fluoxetine use. Am J Psychiatry. 1991; 148:392. http://www.ncbi.nlm.nih.gov/pubmed/1992847?dopt=AbstractPlus

250. Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry. 1989; 146:1515. http://www.ncbi.nlm.nih.gov/pubmed/2510522?dopt=AbstractPlus

251. Liebowitz MR, Hollander E, Schneier F et al. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. J Clin Psychopharmacol. 1989; 9:423-7. http://www.ncbi.nlm.nih.gov/pubmed/2687337?dopt=AbstractPlus

252. Jenike MA, Baer L, Greist JH. Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol. 1990; 10:122-4. http://www.ncbi.nlm.nih.gov/pubmed/2140372?dopt=AbstractPlus

253. Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull. 1990; 26:285-90. http://www.ncbi.nlm.nih.gov/pubmed/2274627?dopt=AbstractPlus

254. Marcus MD, Wing RR, Ewing L et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. Am J Psychiatry. 1990; 147:876-81. http://www.ncbi.nlm.nih.gov/pubmed/2192563?dopt=AbstractPlus

255. Gwirtsman HE, Guze BH, Yager J et al. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry. 1990; 51:378-82. http://www.ncbi.nlm.nih.gov/pubmed/2102671?dopt=AbstractPlus

256. Ramirez LC, Rosenstock J, Strowig S et al. Effective treatment of bulimia with fluoxetine, a serotonin reuptake inhibitor, in a patient with type I diabetes mellitus. Am J Med. 1990; 88:540-1. http://www.ncbi.nlm.nih.gov/pubmed/2140012?dopt=AbstractPlus

257. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1989; 146:352-3.

258. Feder R. Fluoxetine-induced mania. J Clin Psychiatry. 1990; 51:524-5. http://www.ncbi.nlm.nih.gov/pubmed/2258369?dopt=AbstractPlus

259. Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol. 1990; 5:191-4. http://www.ncbi.nlm.nih.gov/pubmed/2230063?dopt=AbstractPlus

260. Basel Pharmaceutical. Tegretol (carbamazepine) chewable tablets and tablets prescribing information. Ardsley, NY; 1991 May.

261. Basel Pharmaceutical. Tegretol (carbamazepine) suspension prescribing information. Ardsley, NY; 1991 May.

262. Grimsley SR, Jann MW, Carter JG et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther. 1991; 50:10-5. http://www.ncbi.nlm.nih.gov/pubmed/1855347?dopt=AbstractPlus

263. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry. 1990; 51:3.

264. Carbamazepine/fluoxetine. In Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lipincott Co; 1991 (Apr):174a.

265. Kincaid RL, McMullin MM, Crookman SB et al. Report of a fluoxetine fatality. J Anal Toxicol. 1990; 14:327-9. http://www.ncbi.nlm.nih.gov/pubmed/2263071?dopt=AbstractPlus

266. Rohrig TP, Prouty RW. Fluoxetine overdose: a case report. J Anal Toxicol. 1989; 13:305-7. http://www.ncbi.nlm.nih.gov/pubmed/2693835?dopt=AbstractPlus

267. Achamallah NS, Decker DH. Mania induced by fluoxetine in an adolescent. Am J Psychiatry. 1991; 148:1404. http://www.ncbi.nlm.nih.gov/pubmed/1897627?dopt=AbstractPlus

268. Steiner W. Fluoxetine-induced mania in a patient with obsessive-compulsive disorder. Am J Psychiatry. 1991; 148:1403-4. http://www.ncbi.nlm.nih.gov/pubmed/1897626?dopt=AbstractPlus

269. Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy. Am J Psychiatry. 1990; 147:947-8. http://www.ncbi.nlm.nih.gov/pubmed/2356881?dopt=AbstractPlus

270. Moore JL, Rodriguez R. Toxicity of fluoxetine overdose. Am J Psychiatry. 1990; 147:1089. http://www.ncbi.nlm.nih.gov/pubmed/2375446?dopt=AbstractPlus

271. Musher JS. Anorgasmia with the use of fluoxetine. Am J Psychiatry. 1990; 147:948. http://www.ncbi.nlm.nih.gov/pubmed/2356882?dopt=AbstractPlus

272. Neill JR. Penile anesthesia associated with fluoxetine use. Am J Psychiatry. 1991; 148:1603. http://www.ncbi.nlm.nih.gov/pubmed/1928483?dopt=AbstractPlus

273. Browning WN. Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine. Am J Psychiatry. 1990; 147:1089. http://www.ncbi.nlm.nih.gov/pubmed/2375445?dopt=AbstractPlus

274. Lipinski JF, Mallya G, Zimmerman P et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989; 50:339-42. http://www.ncbi.nlm.nih.gov/pubmed/2549018?dopt=AbstractPlus

275. Lipinski JF, Mallya G, Zimmerman P et al. Akathisia and fluoxetine. J Clin Psychiatry. 1990; 51:212.

276. Falon BA, Liebowitz MR. Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol. 1991; 11:147-8. http://www.ncbi.nlm.nih.gov/pubmed/2056144?dopt=AbstractPlus

277. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine. Am J Psychiatry. 1991; 148:1403. http://www.ncbi.nlm.nih.gov/pubmed/1897625?dopt=AbstractPlus

278. Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry. 1990; 51:169. http://www.ncbi.nlm.nih.gov/pubmed/2324084?dopt=AbstractPlus

279. Vincent A, Douville M, Baruch P. Serum sickness induced by fluoxetine. Am J Psychiatry. 1991; 148:1602-3. http://www.ncbi.nlm.nih.gov/pubmed/1928481?dopt=AbstractPlus

280. Vishwanath BM, Navalgund AA, Cusano W et al. Fluoxetine as a cause of SIADH. Am J Psychiatry. 1991; 148:542-3. http://www.ncbi.nlm.nih.gov/pubmed/2006703?dopt=AbstractPlus

281. Cohen BJ, Mahelsky M, Adler L. More cases of SIADH with fluoxetine. Am J Psychiatry. 1990; 147:948-9. http://www.ncbi.nlm.nih.gov/pubmed/2356883?dopt=AbstractPlus

282. Mandalos GE, Szarek BL. Dose-related paranoid reaction associated with fluoxetine. J Nerv Ment Dis. 1990; 178:57-8. http://www.ncbi.nlm.nih.gov/pubmed/2295892?dopt=AbstractPlus

283. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148:705-13. http://www.ncbi.nlm.nih.gov/pubmed/2035713?dopt=AbstractPlus

284. Feighner JP, Boyer WF, Tyler DL et al. Adverse consequences of fluoxetine-MAOI combination. J Clin Psychiatry. 1990; 51:222-5. http://www.ncbi.nlm.nih.gov/pubmed/2347858?dopt=AbstractPlus

285. Rosenstein DL, Takeshita J, Nelson JC. Fluoxetine-induced elevation and prolongation of tricyclic levels in overdose. Am J Psychiatry. 1991; 148:807. http://www.ncbi.nlm.nih.gov/pubmed/2035725?dopt=AbstractPlus

286. Extein IL. Recent fluoxetine treatment and complications of tricyclic therapy. Am J Psychiatry. 1991; 148:1601-2. http://www.ncbi.nlm.nih.gov/pubmed/1928480?dopt=AbstractPlus

287. Alessi N, Bos T. Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. Am J Psychiatry. 1991; 148:1605-6. http://www.ncbi.nlm.nih.gov/pubmed/1928487?dopt=AbstractPlus

288. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1990; 147:790-800.

289. Naranjo CA, Kadlec KE, Sanhueza P et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990; 47:490-8. http://www.ncbi.nlm.nih.gov/pubmed/2328557?dopt=AbstractPlus

290. FDA Press Office. Talk paper: FDA denies Scientology petition against Prozac. [T91-46.] Rockville, MD: Food and Drug Administration; 1991 Aug 1.

291. Wolfe SM, Hellander I. Citizen’s petition for revision of fluoxetine (Prozac) labeling to Dr. David Kessler, Commissioner, Food and Drug Administration. Washington, DC: Public Citizen; 1991 May 23.

292. Anon. No “credible evidence” to conclude that Lilly’s Prozac or other anti-depressants cause or intensify suicidality, FDA advisory committee determines. FDA Rep Prescrip OTC Pharmaceut. 1991; 53(Sep 23):3-4.

293. Teicher MH, Glod CA, Cole JO. Preoccupation with suicide in patients treated with fluoxetine. Am J Psychiatry. 1991; 148:1091-2. http://www.ncbi.nlm.nih.gov/pubmed/1898490?dopt=AbstractPlus

294. Hoover CE. Suicidal ideation not associated with fluoxetine. Am J Psychiatry. 1991; 148:543-4. http://www.ncbi.nlm.nih.gov/pubmed/2006704?dopt=AbstractPlus

295. Chouinard G. Fluoxetine and preoccupation with suicide. Am J Psychiatry. 1991; 148:1258-9. http://www.ncbi.nlm.nih.gov/pubmed/1679300?dopt=AbstractPlus

296. Teicher MH, Glod CA, Cole JO. Fluoxetine and preoccupation with suicide. Am J Psychiatry. 1991; 148:1260-2.

297. McGrath BJ, Stoukides CA. Fluoxetine and suicidal ideation. DICP. 1991; 25:607-9. http://www.ncbi.nlm.nih.gov/pubmed/1877271?dopt=AbstractPlus

298. Dista. Prozac (fluoxetine hydrochloride) capsules and oral solution prescribing information. In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:943-7.

299. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther. 1993; 53:84-8. http://www.ncbi.nlm.nih.gov/pubmed/8257462?dopt=AbstractPlus

300. Mills KC. Serotonin syndrome. Am Fam Physician. 1995; 52:11475-82.

301. Reynolds RD. Serotonin syndrome: what family physicians need to know. Am Fam Physician. 1995; 52:1263-71. http://www.ncbi.nlm.nih.gov/pubmed/7572545?dopt=AbstractPlus

302. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994; 330:1021-2. http://www.ncbi.nlm.nih.gov/pubmed/8121457?dopt=AbstractPlus

303. Sporer KA. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995; 13:94-104. http://www.ncbi.nlm.nih.gov/pubmed/7576268?dopt=AbstractPlus

304. Evans ML, Kortas KJ. Potential interaction between isoniazid and selective serotonin reuptake inhibitors. Am J Health-Syst Pharm. 1995; 52:2135-6. http://www.ncbi.nlm.nih.gov/pubmed/8535949?dopt=AbstractPlus

305. Neuvonen PJ, Pohjola-Sintonen S, Tacke U. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993; 342:1419. http://www.ncbi.nlm.nih.gov/pubmed/7901695?dopt=AbstractPlus

306. Spigset O, Mjorndal T, Lovhelm O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ. 1993; 306:248.

307. Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother. 1994; 28:732-5. http://www.ncbi.nlm.nih.gov/pubmed/7919561?dopt=AbstractPlus

308. Zornberg GL, Hegarty JD. Adverse interaction between propoxyphene and phenelzine. Am J Psychiatry. 1993; 150:1270-1. http://www.ncbi.nlm.nih.gov/pubmed/8328578?dopt=AbstractPlus

309. Brodribb TR, Downey M, Gilbar PJ. Efficacy and adverse effects of moclobemide. Lancet. 1994; 343:475. http://www.ncbi.nlm.nih.gov/pubmed/7905962?dopt=AbstractPlus

310. Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol. 1994; 14:144-5. http://www.ncbi.nlm.nih.gov/pubmed/8195456?dopt=AbstractPlus

311. Somerset Pharmaceuticals. Eldepryl (selegiline) tablets prescribing information (dated 1994 Sep). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995(Supp A):A157-8.

312. Somerset Pharmaceuticals. Eldepryl (selegiline) tablets prescribing information (dated 1993 Jan). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:2430-2.

313. Blume CD. Dear doctor letter regarding use of Eldepryl. Tampa, FL: Somerset Pharmaceuticals; 1994 Nov 14.

314. Deitch MW. Dear doctor letter regarding use of Effexor. Philadelphia, PA: Wyeth-Ayerst Laboratories; 1994 Dec 28.

315. Wyeth-Ayerst Laboratories. Effexor (venlafaxine) tablets prescribing information In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:2664-8.

316. Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm. 1993; 12:222-5. http://www.ncbi.nlm.nih.gov/pubmed/8491079?dopt=AbstractPlus

317. Messiha FS. Fluoxetine: Adverse effects and drug-drug interactions. J Toxicol Clin Toxicol. 1993; 31:603-30. http://www.ncbi.nlm.nih.gov/pubmed/8254702?dopt=AbstractPlus

318. Hansen TE, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. Am J Psychiatry. 1990; 147:949-50. http://www.ncbi.nlm.nih.gov/pubmed/2356884?dopt=AbstractPlus

319. Jahr JS, Pisto JD, Gitlin MC et al. The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg. 1994; 79:189-91. http://www.ncbi.nlm.nih.gov/pubmed/8010436?dopt=AbstractPlus

320. Dursun SM, Mathew VM, Revelay MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet. 1993; 342:442-3.

321. Anon. Carbamazepine (Tegretol) Interactions. Fluoxetine (Prozac). In: Hansten PD, Horn JR, eds. Drug interactions & updates. Applied Therapeutics, Inc.; Updates, April 1994:744.

322. Skop BP, Finkelstein JA, Mareth TR et al. The serotonin syndrome associated with paroxetine, and over-the-counter cold remedy, and vascular disease. Am J Emerg Med. 1994; 12:642-44. http://www.ncbi.nlm.nih.gov/pubmed/7945606?dopt=AbstractPlus

323. Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry. 1993; 150:837. http://www.ncbi.nlm.nih.gov/pubmed/8480837?dopt=AbstractPlus

324. Beasley CM, Masica DN, Heiligenstein JH et al. Possible monoamine oxidase inhibitor–serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol. 1993; 13:312-20. http://www.ncbi.nlm.nih.gov/pubmed/8227489?dopt=AbstractPlus

325. Wyeth-Ayerst. Redux (dexfenfluramine hydrochloride) capsules prescribing information. Philadelphia, PA; 1996 April 29.

326. Miller F, Friedman R, Miller F, Tanenbaum J et al. Disseminated intravascular coagulation and acute myoglobinuric renal failure: A consequence of the serotonin syndrome. J Clin Psychopharmacol. 1991; 11:277-9. http://www.ncbi.nlm.nih.gov/pubmed/1918432?dopt=AbstractPlus

327. Jermaine DM. Potential fluoxetine-selegiline interaction. Ann Pharmacother. 1992; 26:1300.

328. Solvay. Luvox (fluvoxamine maleate) tablets prescribing information (dated 1996 Aug). In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997:2723-7.

329. SmithKline Beecham. Paxil (paroxetine hydrochloride) tablets and oral suspension prescribing information. 1999 May.

330. Pfizer. Zoloft (sertraline hydrochloride) tablets and oral concentrate prescribing information. 2000 Jan.

332. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia. 1996; 16:323-7. http://www.ncbi.nlm.nih.gov/pubmed/8869767?dopt=AbstractPlus

333. Glaxo Wellcome. Imitrex (sumatriptan succinate) injection prescribing information. Research Triangle Park, NC; 1996 May.

334. Szabo CP. Fluoxetine and sumatriptan: possibly a counterproductive combination. J Clin Psychiatry. 1995; 56:37-8. http://www.ncbi.nlm.nih.gov/pubmed/7836342?dopt=AbstractPlus

335. Blier P, Bergeron R. The safety of concomitant use of sumatriptan and antidepressant treatments. J Clin Psychopharmacol. 1995; 15:106-9. http://www.ncbi.nlm.nih.gov/pubmed/7782482?dopt=AbstractPlus

336. Diamond S. The use of sumatriptan in patients on monoamine oxidase inhibitors. Neurology. 1995; 45:1039-40. http://www.ncbi.nlm.nih.gov/pubmed/7783861?dopt=AbstractPlus

337. Wing Y-K, Clifford EM, Sheehan BD et al. Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology. 1996; 124:377-9. http://www.ncbi.nlm.nih.gov/pubmed/8739554?dopt=AbstractPlus

338. Glaxo Wellcome, Research Triangle Park, NC: Personal communication.

339. Reviewers’ comments (personal observations) on sumatriptan succinate 28:92.

340. Janssen Pharmaceutica. Hismanal (astemizole tablets) prescribing information. Titusville, NJ. 1998 Feb.

341. Klausner MA. Dear doctor letter regarding important drug warning of Hismanal (astemizole). Titusville, NJ: Janssen Pharmaceutica; 1998 Feb.

342. Hoechst Marion Roussel. Seldane-D (terfenadine and pseudoephedrine hydrochloride) extended-release tablets prescribing information. Kansas City, MO; 1997 Sep.

343. The United States pharmacopeia, 24th rev, and The national formulary, 19th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 2000:738-40.

344. Food and Drug Administration. Prozac (fluoxetine HCl) Pulvules and solution [October 7, 1999: Lilly]. MedWatch drug labeling changes. Rockville, MD; December, 1999. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm

345. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000; 157(Suppl 4):1-45.

346. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull. 1992; 28:253-6.

347. Liu B, Anderson G, Mittmann N et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998; 351:1303-7. http://www.ncbi.nlm.nih.gov/pubmed/9643791?dopt=AbstractPlus

348. Thapa PB, Gideon P, COst TW et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998; 339:875-82. http://www.ncbi.nlm.nih.gov/pubmed/9744971?dopt=AbstractPlus

349. Small GW, Rabins PV, Barry PB et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA. 1997; 278:1363-1371. http://www.ncbi.nlm.nih.gov/pubmed/9343469?dopt=AbstractPlus

350. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry. 1997; 154(Suppl):1-39.

351. National Institutes of Health Office of Medical Applications of Research. NIH consensus statement: diagnosis and treatment of depression in late life. 1991; 9;1-27.

352. Lebowitz BD, Pearson JL, Schneider LS et al. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA. 1997; 278:1186-90. http://www.ncbi.nlm.nih.gov/pubmed/9326481?dopt=AbstractPlus

353. Fava M. New approaches to treatment of refractory depression. J Clin Psychiatry. 2000:61 (Suppl 1):26-32.

354. Nelson JC. Augmentation strategies in depression 2000. J Clin Psychiatry. 2000:61(Suppl 2):13-9.

355. American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders (revision). Am J Psychiatry. 2000; 157(Suppl 1):1-39.

356. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 1998; 37(Suppl 10):63S-83S. http://www.ncbi.nlm.nih.gov/pubmed/9785729?dopt=AbstractPlus

357. Agras WS, Rossiter EM, Arnow B et al. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry. 1992; 149:82-7. http://www.ncbi.nlm.nih.gov/pubmed/1728190?dopt=AbstractPlus

358. Herzog DB, Sacks NR. Bulimia nervosa: comparison of treatment responders vs. nonresponders. Psychopharmacol Bull. 1993; 29:121-5. http://www.ncbi.nlm.nih.gov/pubmed/8378505?dopt=AbstractPlus

359. Peterson CB, Mitchell JE. Psychosocial and pharmacological treatment of eating disorders: a review of research findings. J Clin Psychology. 1999; 55:685-97.

360. Kennedy SH, Eisfeld BS, Dickens SE et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000; 61:276-81. http://www.ncbi.nlm.nih.gov/pubmed/10830148?dopt=AbstractPlus

361. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med. 1995; 332:1529-34. http://www.ncbi.nlm.nih.gov/pubmed/7739706?dopt=AbstractPlus

362. Romano S, Judge R, Dillon J et al. The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clin Ther. 1999; 21:615-33. http://www.ncbi.nlm.nih.gov/pubmed/10363729?dopt=AbstractPlus

363. Pearlstein TB, Stone AB, Lund SA et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997; 17:261-6. http://www.ncbi.nlm.nih.gov/pubmed/9241004?dopt=AbstractPlus

364. Su TP, Schmidt PJ, Danaceau MA et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology. 1997; 16:346-56. http://www.ncbi.nlm.nih.gov/pubmed/9109106?dopt=AbstractPlus

365. Dear doctor letter regarding the addition of a black box warning to thioridazine (Mellaril) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2000 Jul.

366. Eli Lilly and Company. Sarafem (fluoxetine hydrochloride) capsules prescribing information. Indianapolis, IN; 2002 Jun 12.

367. Ferslew KE, Hagardorn AN, Harlan GC et al. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci. 1998; 43:1082-5. http://www.ncbi.nlm.nih.gov/pubmed/9729831?dopt=AbstractPlus

368. Fluoxetine (Prozac) interactions: risperidone (Risperdal). In: Hansten PD, Horn JR. Drug interactions & updates. Vancouver, WA: Applied Therapeutics; 1997:296.

369. Fluoxetine (Prozac) interactions: Propranolol (Inderal). In: Hansten PD, Horn JR. Drug interactions & updates. Vancouver, WA: Applied Therapeutics; 1997:295.

370. Gramaekers JG, Muntjewerff ND, O’Hanlon JF. A comparative study of acute and subchronic effects of doxepin, fluoxetine, and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol. 1995; 39:397-404. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1365127&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7640146?dopt=AbstractPlus

371. Ball SE, Ahern D, Scatina J et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997; 43:619-26. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2042781&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9205822?dopt=AbstractPlus

372. Harris MG, Benfield P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging. 1995; 6:64-84. http://www.ncbi.nlm.nih.gov/pubmed/7696780?dopt=AbstractPlus

373. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDs: a randomized, placebo-controlled trial. Am J Psychiatry. 1999; 156:101-7. http://www.ncbi.nlm.nih.gov/pubmed/9892304?dopt=AbstractPlus

374. Jeppesen U, Gram LF, Vistisen K et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996; 51:73-8. http://www.ncbi.nlm.nih.gov/pubmed/8880055?dopt=AbstractPlus

375. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm. 1992; 11:930-57. http://www.ncbi.nlm.nih.gov/pubmed/1464219?dopt=AbstractPlus

376. Pigott TA. OCD: where the serotonin selectivity story begins. J Clin Psychiatr. 1996; 57(Suppl. 6):11-20.

377. Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 1992; 7(Suppl. 2):37-41. http://www.ncbi.nlm.nih.gov/pubmed/1484177?dopt=AbstractPlus

378. Carpenter LL, McDougle CJ, Epperson CN et al. A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Saf. 1996; 15:116-34. http://www.ncbi.nlm.nih.gov/pubmed/8884163?dopt=AbstractPlus

379. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J child Adolesc Psychopharmacol. 2000; 10:27-34. http://www.ncbi.nlm.nih.gov/pubmed/10755579?dopt=AbstractPlus

380. Borg S, Brodin K. Antidepressant drugs. In: Dukes MNG, ed. Meyler’ side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:35-41.

381. Kabel DI, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res. 1996; 20:780-4. http://www.ncbi.nlm.nih.gov/pubmed/8800399?dopt=AbstractPlus

382. Slywka S, Hart LL. Fluoxetine in alcoholism. Ann Pharmacotherapy. 1993; 27:1066-7.

383. Schneier FR, Liebowitz MR, Davies SO et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1990; 10:119-21. http://www.ncbi.nlm.nih.gov/pubmed/2341585?dopt=AbstractPlus

384. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry. 2002; 159(Suppl):1-50.

385. Zornberg, GL, Harrison GP. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol. 1993; 13:397-408. http://www.ncbi.nlm.nih.gov/pubmed/8120153?dopt=AbstractPlus

386. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997; 32(Suppl 1):1-21. http://www.ncbi.nlm.nih.gov/pubmed/9068931?dopt=AbstractPlus

387. Hughes CW, Emslie GJ, Crismon ML et al. The Texas children’s medication algorithm project: report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38:1442-54. http://www.ncbi.nlm.nih.gov/pubmed/10560232?dopt=AbstractPlus

388. Ambrosini PJ. A review of pharmacotherapy of major depression in children and adolescents. Psychiatric Ser. 2000; 51:627-33.

389. Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997; 54:1031-7. http://www.ncbi.nlm.nih.gov/pubmed/9366660?dopt=AbstractPlus

390. Waslick BD, Walsh BT, Greenhill LL et al. Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression. J Affect Disord. 1999; 56:227-36. http://www.ncbi.nlm.nih.gov/pubmed/10701482?dopt=AbstractPlus

391. Emslie GJ, Rush AJ, Weinberg WA et al. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety. 1998; 7:32-9. http://www.ncbi.nlm.nih.gov/pubmed/9592630?dopt=AbstractPlus

392. Pliszka SR, Greenhill LL, Crismon ML et al. The Texas Children’s Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part II: Tactics. J Am Acad Child Adolesc Psychiatry. 2000; 39:920-7. http://www.ncbi.nlm.nih.gov/pubmed/10892235?dopt=AbstractPlus

393. Kara H, Aydin S, Agargun MY et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996; 156:1631-2. http://www.ncbi.nlm.nih.gov/pubmed/8863556?dopt=AbstractPlus

394. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline, and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol. 1998; 159:425-7. http://www.ncbi.nlm.nih.gov/pubmed/9649255?dopt=AbstractPlus

395. Rosen RC, Lane R, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999; 19:67-85. http://www.ncbi.nlm.nih.gov/pubmed/9934946?dopt=AbstractPlus

396. Novartis. Clozaril (clozapine) tablets prescribing information. East Hanover, NJ; 1999 Sept.

397. Ellingrod VL. Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature. Pharmacotherapy. 1998; 18:936-60. http://www.ncbi.nlm.nih.gov/pubmed/9758307?dopt=AbstractPlus

398. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry. 1998; 35:64-70.

399. Ozdemir V, Naranjo CA, Shulman RW et al. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998; 18:198-207. http://www.ncbi.nlm.nih.gov/pubmed/9617978?dopt=AbstractPlus

400. Anon. Prozac Weekly. Med Lett Drugs Ther. 2001; 43:27. http://www.ncbi.nlm.nih.gov/pubmed/11283472?dopt=AbstractPlus

401. Schmidt ME, Fava M, Robinson JM et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry. 2000; 61:851-7. http://www.ncbi.nlm.nih.gov/pubmed/11105738?dopt=AbstractPlus

402. Burke WJ, Hendricks SE, McArthur-Miller D et al. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol. 2000; 43:423-7.

403. Claxton A, de Klerk E, Parry M et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. 2000; 61:928-32.

404. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 1994; 151(Suppl 12):1-29.

405. Cohen LS, Miner C, Brown EW et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol. 2002; 100:435-44. http://www.ncbi.nlm.nih.gov/pubmed/12220761?dopt=AbstractPlus

406. Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatr. 2002; 41:1205-15.

407. Chan RTW, Rey JM, Hazell PL. Clinical practice guidelines for depression in young people: are the treatment recommendations outdated? Med J Aust. 2002; 177:440-3.

408. Geller DA, Hoog SL, Heiligenstein JH et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatr. 2001; 40:773-9.

409. Grados MA, Riddle MA. Pharmacological treatment of childhood obsessive-compulsive disorder: from theory to practice. J Clin Child Psychol. 2001; 30:67-79. http://www.ncbi.nlm.nih.gov/pubmed/11294079?dopt=AbstractPlus

410. Romano SJ, Halmi KA, Sarkar NP et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatr. 2002; 159:96-102. http://www.ncbi.nlm.nih.gov/pubmed/11772696?dopt=AbstractPlus

411. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000; 10:27-34. http://www.ncbi.nlm.nih.gov/pubmed/10755579?dopt=AbstractPlus

412. Bondolfi G, Eap CB, Bertschy G et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients. Pharmacopsychiatry. 2002; 35:50-6. http://www.ncbi.nlm.nih.gov/pubmed/11985287?dopt=AbstractPlus

413. US Food and Drug Administration. FDA approves Prozac for pediatric use to treat depression and OCD. FDA Talk Paper. Rockville, MD: FDA; 2002 Jan 3.

414. Tollefson GD, Rampey AH, Potvin JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994; 51:559-67. http://www.ncbi.nlm.nih.gov/pubmed/8031229?dopt=AbstractPlus

415. Greist JH, Jefferson JW, Kobak KA et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry. 1995; 52:53-60. http://www.ncbi.nlm.nih.gov/pubmed/7811162?dopt=AbstractPlus

416. Pigott TA, Pato MT, Bernstein SE et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990; 47:926-32.x http://www.ncbi.nlm.nih.gov/pubmed/2222131?dopt=AbstractPlus

417. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. (text revision) Washington, DC: American Psychiatric Association; 2000; 456-63:

418. Michelson D, Allgulander C, Dantendorfer K et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001; 179:514-8. http://www.ncbi.nlm.nih.gov/pubmed/11731354?dopt=AbstractPlus

419. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry. 1998; 155(Suppl):1-34.

420. Montgomery SA, McIntyre A, Osterheider M et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1993; 3:143-52. http://www.ncbi.nlm.nih.gov/pubmed/8364350?dopt=AbstractPlus

421. Lopez-Ibor JJ Jr., Saiz J, Cottraux J et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996; 6:111-8.

422. Christenson GA, Mackenzie TB, Mitchell JE et al. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry. 1991; 148:1566-71. http://www.ncbi.nlm.nih.gov/pubmed/1928474?dopt=AbstractPlus

423. Streichenwein SM, Thornby JI. A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry. 1995; 152:1192-6. http://www.ncbi.nlm.nih.gov/pubmed/7625469?dopt=AbstractPlus

424. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry. 1996; 57(Suppl.10):51-8; discussion 59-60. http://www.ncbi.nlm.nih.gov/pubmed/8917132?dopt=AbstractPlus

425. Davidson JR. The long-term treatment of panic disorder. J Clin Psychiatry. 1998; 59(Suppl. 8):17-21; discussion: 22-3. http://www.ncbi.nlm.nih.gov/pubmed/9707158?dopt=AbstractPlus

426. Baldwin DS, Birttwwistle J. The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry. 1998; 59(Suppl. 8):39-44; discussion: 45-6. http://www.ncbi.nlm.nih.gov/pubmed/9707161?dopt=AbstractPlus

427. Gorman JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry. 1997; 58(Suppl. 14):54-8; discussion 59.

428. Westenberg HG. Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? J Affect Dis. 1996; 40:85-93.

429. deh Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical standpoint. J Clin Psychiatry. 1998; 59:30-6; discussion 37-8.

430. Treatment of panic disorder. NIH Consensus Statement Online 1991 Sep 25-27; 9(2):1- 24.

431. Ballenger MC, Davidson JRT, Lecrubier Y et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998; 59(Suppl 8):47-54

432. Wilens TE, Cohen L, Biederman J et al. Fluoxetine pharmacokinetics in pediatric patients. J Clin Psychopharmacol 2002; 22:568-75. http://www.ncbi.nlm.nih.gov/pubmed/12454556?dopt=AbstractPlus

433. Palmer CJ, Yates WR, Trotter L. Childhood trichotillomania: successful treatment with fluoxetine following an SSRI failure. Psychosomatics. 1999; 40:526-8. http://www.ncbi.nlm.nih.gov/pubmed/10581985?dopt=AbstractPlus

434. Winchel RM, Jones JS, Stanley B et al. Clinical characteristics of trichotillomania and its response to fluoxetine. J Clin Psychiatry. 1992; 53:304-8. http://www.ncbi.nlm.nih.gov/pubmed/1517191?dopt=AbstractPlus

435. Michelson D, Pollack M, Lydiard RB et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. 1999; 174:213-8. http://www.ncbi.nlm.nih.gov/pubmed/10448445?dopt=AbstractPlus

436. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder: Collaborative Paroxetine Panic Study Investigators. Acta Psychiatrica Scandinavica. 1997; 95:153-60. http://www.ncbi.nlm.nih.gov/pubmed/9065681?dopt=AbstractPlus

437. Michelson D, Lydiard RB, Pollack M et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry. 1998: 155:1570-7.

438. van Minnen A, Hoogduin KA, Keijsers GP et al. Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. Arch Gen Psychiatry. 2003; 60:517-22. http://www.ncbi.nlm.nih.gov/pubmed/12742873?dopt=AbstractPlus

439. Sheikha SH, Wagner KD, Wagner RF Jr. Fluoxetine treatment of trichotillomania and depression in a prepubertal child. Cutis. 1993; 51:50-2. http://www.ncbi.nlm.nih.gov/pubmed/8419112?dopt=AbstractPlus

440. Koran LM, Ringold A, Hewlett W. Fluoxetine for trichotillomania: an open clinical trial. Psychopharmacol Bull. 1992; 28:145-9. http://www.ncbi.nlm.nih.gov/pubmed/1513916?dopt=AbstractPlus

441. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1998; 37(Suppl. 10S):27S-45S. http://www.ncbi.nlm.nih.gov/pubmed/9785727?dopt=AbstractPlus

442. Anon. FDA statement regarding the anti-depressant Paxil for pediatric population. FDA Talk Paper. Rockville, MD: Food and Drug Administration; 2003 Jun 30. T03-43.

443. Food and Drug Administration. Questions and answers on Paxil (paroxetine hydrochloride). From: Center for Drug Evaluation and Research web site. 2003 Jun 23.

444. Calabrese JR, Londborg PD, Shelton MD et al. Citalopram treatment of fluoxetine-intolerant patients. J Clin Psychiatry.2003; 64:562-7. http://www.ncbi.nlm.nih.gov/pubmed/12755660?dopt=AbstractPlus

445. Anon. FDA issues public health advisory entitled: Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). FDA Talk Paper. Rockville, MD: Food and Drug Administration; 2003 Oct 27. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm

446. Anon. Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). FDA Public Health Advisory. Rockville, MD: Food and Drug Administration; 2003 Oct 27. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm168828.htm

447. Anon. SSRIs safe for children? Med Lett Drugs Ther.2003; 45:53-4.

448. Eli Lilly & Co. Symbyax (olanzapine and fluoxetine HCl capsules) prescribing information. Indianapolis, IN; 2011 Aug.

449. Barak Y, Kimhi R, Weizman R. Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients? Int Clin Psychopharmacol. 2000; 15:53-6.

450. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatr. 1994; 164:549-50.

451. Reviewers’ comments (personal observations) on citalopram 28:16.04.20.

452. de Abajo FJ, García Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case control study. Br Med J. 1999; 319:1106-9. http://www.ncbi.nlm.nih.gov/pubmed/10531103?dopt=AbstractPlus

453. Shuster J. SSRIs and upper gastrointestinal bleeding? Cutaneous reactions to psychotropic drugs; atrial fibrillation and anabolic steroids; accidental olanzapine overdose in a child. Hosp Pharm. 2000; 35:29-30,32.

454. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996; 37:12-6. http://www.ncbi.nlm.nih.gov/pubmed/8600488?dopt=AbstractPlus

455. Boettcher M, Peoples J, Proujansky R et al. Rectal bleeding with use of selective serotonin reuptake inhibitors. J Pediatr Gastroenterol. 1999; 29:522. Abstract No. 133.

456. Goldberg RJ. Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Fam Med. 1998; 7:78-84. http://www.ncbi.nlm.nih.gov/pubmed/9443704?dopt=AbstractPlus

457. Alderman CP, Seshadri P, Ben Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996; 30:1232-4. http://www.ncbi.nlm.nih.gov/pubmed/8913401?dopt=AbstractPlus

458. Tielens JA. Vitamin C for paroxetine- and fluvoxamine-associated bleeding. Am J Psychiatr.1997; 154:883-4. http://www.ncbi.nlm.nih.gov/pubmed/9167526?dopt=AbstractPlus

459. Montejo AL, Llorca G, Izquierdo JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatr.2001;62(Suppl 3):10-21.

460. Landen M, Eriksson E, Agren H et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol . 1999; 19:268-71. http://www.ncbi.nlm.nih.gov/pubmed/10350034?dopt=AbstractPlus

461. Nordeng H, Lindemann R, Perminov KV et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001; 90:288-91. http://www.ncbi.nlm.nih.gov/pubmed/11332169?dopt=AbstractPlus

462. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatr. 1997; 171:391-2. Letter.

463. Catalano G, Catalano MC, Epstein MA et al. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol.2001; 24:158-62. http://www.ncbi.nlm.nih.gov/pubmed/11391127?dopt=AbstractPlus

464. Fu K, Konrad RJ, Hardy RW et al. An unusual multiple drug intoxication case involving citalopram. J Anal Toxicol. 2000; 24:648-50. http://www.ncbi.nlm.nih.gov/pubmed/11043674?dopt=AbstractPlus

465. Rothenhausler HB, Hoberl C, Ehrentrout S et al. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry. 2001; 33:150-2.

466. Hojer J, Personne M, Skagius AS et al. Serotonin syndrome. Several cases of this often overlooked diagnosis. Lakartidningen. 2002; 99:2054-5, 2058-60. [Swedish; with English abstract.] http://www.ncbi.nlm.nih.gov/pubmed/12082784?dopt=AbstractPlus

467. Personne M, Sjoberg G, Persson H. Citalopram overdose—review of cases treated in Swedish hospitals. Clin Toxicol.1997; 35:237-40.

468. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry.1998; 59(Suppl. 5):42-8. http://www.ncbi.nlm.nih.gov/pubmed/9786310?dopt=AbstractPlus

469. Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med. 1994; 23:1371-4. http://www.ncbi.nlm.nih.gov/pubmed/8198316?dopt=AbstractPlus

470. Food and Drug Administration. Antidepressant use in children, adolescents, and adults: class revisions to product labeling. Rockville, MD; 2007 May 2. From the FDA web site. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM173233.pdf

471. Food and Drug Administration. FDA news: FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. Rockville, MD; 2007 May 2. From the FDA web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm

472. Anon. FDA statement on recommendations of the psychopharmacologic drugs and pediatric advisory committees. Rockville, MD; 2004 Sep 16. From the FDA website. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108352.htm

473. American Psychiatric Association (APA). APA responds to FDA’s new warning on antidepressants. Arlington, VA; 2004 Oct. 15. From the APA website. http://www.psych.org/MainMenu/Newsroom/NewsReleases/2004NewsReleases/04-55apaonfdablackboxwarning.aspx

474. American Academy of Child and Adolescent Psychiatry (AACAP). AACAP responds to the new FDA warnings on pediatric antidepressant medications. Washington, D.C; 2004 Oct 15. From the AACAP website. http://www.aacap.org/cs/root/media/press_releases/2004_press_releases/aacap_responds_to_new_fda_warnings_on_pediatric_antidepressant_medication

475. American Academy of Pediatrics (AAP). Children, antidepressants and a black box warning. Washington, D.C; 2004 Oct. 15. From the AAP website. http://www.aap.org/pressroom/aappr-pressreleases.htm

476. Food and Drug Administration. Revisions to medication guide: antidepressant medicines, depression and other serious mental illnesses and suicidal thoughts or actions. Rockville, MD; 2007 May 2. From the FDA web site. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm

477. Gate Pharmaceuticals. Orap (pimozide) tablets prescribing information. Sellersville, PA; 2005 Aug.

478. Ahmed I, Dagincourt PG, Miller LG et al. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry. 1993; 38:62-3. http://www.ncbi.nlm.nih.gov/pubmed/8448725?dopt=AbstractPlus

479. Hansen-Grant S, Silk KR, Guthrie S. Fluoxetine-pimozide interaction. Am J Psychiatry. 1993 Nov; 150:1751-2. (IDIS 321569)

480. Sanz EJ, De-Las-Cuevas C, Kiuru A et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005; 365:482-7. http://www.ncbi.nlm.nih.gov/pubmed/15705457?dopt=AbstractPlus

481. Nordeng H, Lindemann R, Perminov KV et al. Neonatal withdrawal syndrome after in utero exposure to selective serotonin-reuptake inhibitors. Acta Paediatr. 2001; 90:288-91. http://www.ncbi.nlm.nih.gov/pubmed/11332169?dopt=AbstractPlus

482. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatr. 1997; 171:391-2.

483. Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998; 279:609-10. http://www.ncbi.nlm.nih.gov/pubmed/9486756?dopt=AbstractPlus

484. Dear healthcare professional letter regarding changing the Pregnancy subsection of the Precautions section in the labels for Paxil (paroxetine HCl) and Paxil (paroxetine HCl) CR. Philadelphia, PA: GlaxoSmithKline; 2005 Sep.

485. Hendrick V, Smith LM, Suri R et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol. 2003; 188:812-5. http://www.ncbi.nlm.nih.gov/pubmed/12634662?dopt=AbstractPlus

486. SmithKlineBeecham Pharmaceuticals. Paxil (paroxetine hydrochloride) tablets and oral suspension prescribing information. 2005 Sep.

487. Dalton SO, Johansen C, Mellemkjaer L et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003; 163:59-64. http://www.ncbi.nlm.nih.gov/pubmed/12523917?dopt=AbstractPlus

488. van Walraven C, Mamdani MM, Wells PS et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001; 323:655-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=55923&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/11566827?dopt=AbstractPlus

489. Morag I, Batash D, Keidar R et al. Paroxetine use throughout pregnancy: does it pose any risk to the neonate? J Toxicol Clin Toxicol. 2004; 42:97-100.

490. Haddad PM, Pal BR, Clarke P et al. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol. 2005; 19:554-7.

491. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005; 292:2372-85.

492. Food and Drug Administration. Public health advisory: combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective serotonin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. Rockville, MD; 2006 Jul 19. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124349.htm

493. US Food and Drug Administration. Drug Safety Communication: Serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. 2011 Jul 26. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm265305.htm

494. US Food and Drug Administration. Drug Safety Communication: Updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications. 2011 Oct 20. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm276251.htm

495. Teva Pharmaceuticals USA Inc. Fluoxetine tablets USP prescribing information. Sellersville, PA: 2012 Jul.

496. Food and Drug Administration. Public health advisory: paroxetine. Rockville, MD; 2005 Dec 8. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051731.htm

497. Dear healthcare professional letter regarding further revisions to the labels for Paxil (paroxetine HCl) and Paxil (paroxetine HCl) CR in the pregnancy precautions and warnings section. Philadelphia, PA: GlaxoSmithKline; 2005 Dec.

498. American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders (3rd ed.). From the APA website. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_12.aspx

501. Abbott Laboratories. Meridia (sibutramine hydrochloride monohydrate) capsules prescribing information. North Chicago, IL; 2006 Aug.

502. Forest Pharmaceuticals, Inc. Celexa (citalopram hydrobromide) tablets and oral solution prescribing information. St. Louis, MO; 2006 Sep.

503. Forest Pharmaceuticals, Inc. Lexapro (escitalopram oxalate) tablets/oral solution prescribing information. St. Louis, MO; 2006 Sep.

504. Trivedi MH, Fava M, Wisniewski SR et al for the STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 354:1243-52. http://www.ncbi.nlm.nih.gov/pubmed/16554526?dopt=AbstractPlus

505. Rush AJ, Trivedi MH, Wisniewski SR et al. for the STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354:1231-42. http://www.ncbi.nlm.nih.gov/pubmed/16554525?dopt=AbstractPlus

506. Rubinow DR. Treatment strategies after SSRI failure—good news and bad news. N Engl J Med. 2006; 354:1305-7. http://www.ncbi.nlm.nih.gov/pubmed/16554533?dopt=AbstractPlus

507. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60:1079-88. http://www.ncbi.nlm.nih.gov/pubmed/14609883?dopt=AbstractPlus

508. Corya SA, Perlis RH, Keck PE. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry. 2006; 67: 798-806.

509. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:277-81.

510. Heikkinen T, Ekblad U, Kero P et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002; 72:184-91. http://www.ncbi.nlm.nih.gov/pubmed/12189365?dopt=AbstractPlus

511. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. 2006; 26:269-76. http://www.ncbi.nlm.nih.gov/pubmed/16466332?dopt=AbstractPlus

512. Bridge JA, Iyengar S, Salary CB et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007; 297:1683-96. http://www.ncbi.nlm.nih.gov/pubmed/17440145?dopt=AbstractPlus

513. Eli Lilly and Company. Cymbalta (duloxetine hydrochloride) delayed-release capsules prescribing information. Indianapolis, IN; 2007 Jun 28.

514. The American Psychiatric Association. APA welcomes FDA antidepressant label changes saying that untreated depression is greatest risk factor for suicide. Arlington, VA; 2007 May 2. Press release.

515. Wyeth Laboratories Inc. Pristiq (desvenlafaxine succinate) extended-release tablets prescribing information. Philadelphia, PA; 2009 Feb.

516. Rabins PV, Blacker D, Rovner BW et al. and the APA Work Group on Alzheimer’s Disease and other Dementias. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias, second edition. Am J Psychiatry. 2007; 164(Suppl 12):5-56.

517. Eli Lilly and Company. Prozac (fluoxetine hydrochloride) Pulvules and delayed-release capsules prescribing information. Indianapolis, IN; 2009 Jun 23.

518. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112-20. http://www.ncbi.nlm.nih.gov/pubmed/15784664?dopt=AbstractPlus

519. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008; 42:1290-7. http://www.ncbi.nlm.nih.gov/pubmed/18628446?dopt=AbstractPlus

520. Ames D, Wirshing WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link?. JAMA. 1993; 269:869-70. http://www.ncbi.nlm.nih.gov/pubmed/8426445?dopt=AbstractPlus

521. Forest Pharmaceuticals, Inc. Celexa (citalopram hydrobromide) tablets and oral solution prescribing information. St. Louis, MO; 2009 Jan.

522. Raskind MA, Peskind ER. Alzheimer’s disease and related disorders. Med Clin North Am. 2001; 85:803-17. http://www.ncbi.nlm.nih.gov/pubmed/11349485?dopt=AbstractPlus

523. Flint AJ, van Reekum R. The pharmacologic treatment of Alzheimer’s disease: a guide for the general psychiatrist. Can J Psychiatry. 1998; 43:689-97. http://www.ncbi.nlm.nih.gov/pubmed/9773218?dopt=AbstractPlus

524. Wilkinson TJ, Begg EJ, Winter AC et al. Incidence and risk factors for hyponatremia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol. 1999; 47:211-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2014168&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10190657?dopt=AbstractPlus

525. ten Holt WL, van Iperen CE, Schrijver G et al. Severe hyponatremia during therapy with fluoxetine. Arch Intern Med. 1996; 156:681-2. http://www.ncbi.nlm.nih.gov/pubmed/8629882?dopt=AbstractPlus

526. Duggal HS, Kithas J. Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine. Am J Psychiatry. 2005; 162:397-8. http://www.ncbi.nlm.nih.gov/pubmed/15677611?dopt=AbstractPlus

527. Hull M, Kottlors M, Braune S. Prolonged coma caused by low sodium and hypo-osmolarity during treatment with citalopram. J Clin Psychopharmacol. 2002; 22:337-8. http://www.ncbi.nlm.nih.gov/pubmed/12006908?dopt=AbstractPlus

528. Odeh M, Beny A, Oliven A. Severe symptomatic hyponatremia during citalopram therapy. Am J Med Sci. 2001; 321:159-60. http://www.ncbi.nlm.nih.gov/pubmed/11217819?dopt=AbstractPlus

529. Eli Lilly & Co. Symbyax (olanzapine and fluoxetine HCl capsules) prescribing information. Indianapolis, IN; 2009 Mar.

530. Eli Lilly and Company. Sarafem (fluoxetine hydrochloride) capsules prescribing information. Indianapolis, IN; 2009 May 4.

531. Eli Lilly and Company. Sarafem (fluoxetine hydrochloride) tablets prescribing information. Indianapolis, IN; 2009 Jun.

532. Taragano FE, Lyketsos CG, Mangone CA et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics. 1997; 38:246-52. http://www.ncbi.nlm.nih.gov/pubmed/9136253?dopt=AbstractPlus

533. Gossen D, de Suray J-M, Vandenhende F et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci. 2002; 4:article 11. http://www.aapspharmsci.org http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2751296&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/12102620?dopt=AbstractPlus

534. Pfizer. Zyvox (linezolid) injection, tablets, and for oral suspension prescribing information. New York, NY: 2008 Jul.

535. Steinberg M, Morin AK. Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. Am J Health-Syst Pharm. 2007; 264:59-62.

536. Taylor JJ, Wilson JW, Estes LL et al. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006; 43:180-7. http://www.ncbi.nlm.nih.gov/pubmed/16779744?dopt=AbstractPlus

537. Sola CL, Bostwick JM, Hart DA et al. Anticipating linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. Mayo Clin Proc. 2006; 81:330-4. http://www.ncbi.nlm.nih.gov/pubmed/16529136?dopt=AbstractPlus

538. Hachem RY, Hicks K, Huen A et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis. 2003; 37:e8-11. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3319403&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/12830431?dopt=AbstractPlus

539. Müller D, Weinmann W, Hermanns-Clausen M. Chinese slimming capsules containing sibutramine sold over the internet: a case series. Dtsch Arztebl Int. 2009; 106:218-22. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2680571&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/19471631?dopt=AbstractPlus

540. Forest Pharmaceuticals, Inc. Viibryd (vilazodone hydrochloride) tablets prescribing information. St Louis, MO; 2011 Apr.

541. Forest Pharmaceuticals, Inc. Celexa (citalopram hydrobromide) tablets and oral solution prescribing information. St. Louis, MO; 2012 Mar.

542. Teva Pharmaceuticals USA Inc. Fluoxetine oral solution USP prescribing information. Sellersville, PA: 2012 Jun.

600. US Food and Drug Administration. FDA drug safety communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 2011 Dec 14. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm276251.htm

602. Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med. 2006; 354:579-87. http://www.ncbi.nlm.nih.gov/pubmed/16467545?dopt=AbstractPlus

603. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008; 17:801-6. http://www.ncbi.nlm.nih.gov/pubmed/18314924?dopt=AbstractPlus

604. Wichman CL, Moore KM, Lang TR et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009; 84:23-7. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2664566&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/19121250?dopt=AbstractPlus

605. Andrade SE, McPhillips H, Loren D et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009; 18:246-52. http://www.ncbi.nlm.nih.gov/pubmed/19148882?dopt=AbstractPlus

606. Wilson KL, Zelig CM, Harvey JP et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011; 28:19-24. http://www.ncbi.nlm.nih.gov/pubmed/20607643?dopt=AbstractPlus

607. US Food and Drug Administration. Public health advisory: treatment challenges of depression in pregnancy and the possibility of persistent hypertension in newborns. Rockville, MD; 2006 Jul 19. From the FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124348.htm

608. Yonkers KA, Wisner KL, Stewart DE et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009; 114:703-13. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103063/pdf/nihms293836.pdf http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3103063&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/19701065?dopt=AbstractPlus

609. Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006; 295:499-507. http://www.ncbi.nlm.nih.gov/pubmed/16449615?dopt=AbstractPlus

610. Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. Br Med J. 2012; 344:d8012.

a. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatr. 2010; 157(Suppl 4):1-45.

Frequently asked questions

View more FAQ

More about fluoxetine

Patient resources

Fluoxetine drug information

Professional resources

Other brands

Prozac, Prozac Weekly, Sarafem

Related treatment guides

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

7.3 / 10

2,183 Reviews

Images

Pill PLIVA 648 is Fluoxetine Hydrochloride 20 mg — Fluoxetine Hydrochloride 20 mg (PLIVA 648)

FLUoxetine (Monograph)

Warning

Introduction

Uses for FLUoxetine

Major Depressive Disorder

Obsessive-Compulsive Disorder (OCD)

Premenstrual Dysphoric Disorder (PMDD)

Eating Disorders

Panic Disorder

Bipolar Disorder

Obesity

Cataplexy

Alcohol Dependence

Myoclonus

Premature Ejaculation

Related/similar drugs

FLUoxetine Dosage and Administration

General

Administration

Oral Administration

Dosage

Pediatric Patients

Major Depressive Disorder

Oral

Obsessive-Compulsive Disorder

Oral

Adults

Major Depressive Disorder

Oral

Obsessive-Compulsive Disorder

Oral

Premenstrual Dysphoric Disorder

Oral

Eating Disorders

Bulimia Nervosa

Anorexia Nervosa†

Panic Disorder

Oral

Bipolar Disorder

Monotherapy for Acute Depressive Episodes†

Combination Therapy for Acute Depressive Episodes

Cataplexy†

Oral

Alcohol Dependence†

Oral

Prescribing Limits

Adults

Oral

Special Populations

Hepatic Impairment

Renal Impairment

Geriatric Patients

Cautions for FLUoxetine

Contraindications

Warnings/Precautions

Warnings

Worsening of Depression and Suicidality Risk

Sensitivity Reactions

Allergic Reactions and Rash

Other Warnings and Precautions

Serotonin Syndrome or Neuroleptic Malignant Syndrome-like Reactions

Activation of Mania or Hypomania

Bipolar Disorder

Seizures

Altered Appetite and Weight

Abnormal Bleeding

Hyponatremia or SIADH

Anxiety and Insomnia

Concomitant Illnesses

Cognitive/Motor Impairment

Long Elimination Half-Life

Withdrawal of Therapy

Use of Fixed Combinations

Electroconvulsive Therapy (ECT)

Specific Populations

Pregnancy

Lactation

Pediatric Use

Geriatric Use

Hepatic Impairment